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Abstract 
 
Metabolites and peptides have a central role in biology that is often overlooked.  
Despite the importance of metabolites in key protein-metabolite interactions (PMIs), the 
extent and identity of these interactions is not known.  Likewise, the extent to which 
short open reading frames (sORFs) in the genome are translated into peptides has also 
been an elusive question.  This dissertation describes the development and application 
of methods to elucidate unknown molecules and interactions critical to understanding 
biology, and the subsequent characterization of the biological roles of these discoveries 
in cells and mice.  
A liquid chromatography-mass spectrometry (LC-MS)-based metabolomics 
approach was used to discover that cholesterol is a ligand for Estrogen Related 
Receptor alpha (ERRα), an orphan nuclear receptor critical in numerous biological 
processes including metabolism, bone growth, and certain cancers.  Despite intense 
study over the 25 years since this nuclear receptor was discovered there is no known 
endogenous ligand for this nuclear receptor.  The discovery of cholesterol as a natural 
ERRα ligand allows for the understanding of how ERRα driven pathways are regulated 
and enables the modulation of receptor activity levels through control of cholesterol 
levels.  
In addition, I also helped pioneer the development of a peptidomics strategy to 
discover novel sORF-encoded polypeptides (SEPs).  Using our approach, we identified 
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86 novel SEPs.  To further the discovery and characterization of these molecules, I 
collaborated on the development of a chemoproteomics approach to discover cysteine-
containing SEPs (ccSEPs), leading to the identification of a further 17 SEPs.  In total, 
103 novel SEP, representing 103 novel human genes with unknown functions are now 
known.  
To characterize SEPs, I developed a new workflow that relies on transcriptomics 
to characterize the functions of novel SEPs, and found that SEPs regulate gene 
expression.  Based on changes in gene expression, SEPs can be assigned to several 
putative pathways.  In one case, this analysis revealed that overexpression of the SEP 
results in a gene expression profile associated with addition of TNFα, which was 
confirmed by further biochemical characterization indicating this SEP promotes 
inflammation. More importantly, by establishing this approach, I have demonstrated a 
general strategy for elucidating the functions of SEPs. 
 
  
v 
 
Acknowledgements 
 
 
 I owe a great deal of thanks to Alan Saghatelian for his guidance and mentoring 
over the course of my Ph.D.  If it were not for his willingness to take me under his wing I 
would never have had this opportunity to learn and grow as a scientist.  His tutelage has 
allowed me to develop the skills to pose interesting scientific questions and answer 
them experimentally.  Alan has fostered a uniquely collegial, collaborative, and friendly 
atmosphere in his laboratory that encourages the free flow of ideas and promotes 
teamwork amongst his students. 
 I would also like to thank my colleagues in the Saghatelian lab, from whom I 
learn every day.  I would like to thank Sarah Slavoff for teaching me everything I know 
about experimental molecular biology, and frequent scientific conversations about 
varied topics—both relevant and irrelevant to our research.  I would like to thank 
Andrew Mitchell who first mentored me when I joined the Saghatelian lab, and taught 
me how to ask the right questions when tackling mountains of information; Yui 
Vinayavekhin for her friendly welcome into the Saghatelian lab and her fastidious 
experimental advice; Anna Mari Lone for her tutelage in peptidomics, and good natured 
sense of humor; Amanda McFedries for her expertise in protein expression and all 
aspects of biochemistry—in addition to her keen insights into prospective business 
ventures; Tejia Zhang for her expertise in metabolomics and advice regarding 
experiments;  Jiao Ma for her dedication, and quick mastery of new topics; Edwin 
Homan for his insights on mass spectrometry and science in general; Bogdan Budnik 
and John Neveau for advice on mass spectrometry and proteomics; Whitney Nolte for 
vi 
 
frequent and unerring advice regarding graduate school and beyond, and Mathias Leidl 
for keeping lab lively and convivial.    
 Additionally, I would like to thank my colleagues in the Verdine Lab and Gregory 
Verdine for their counsel during the course of my Master’s work. 
The support of my family and friends was crucial to the completion of this 
dissertation.  Their encouragement kept me going during the most challenging periods 
of my studies.  In particular I would like to thank Steve Hershman for his prescient 
advice in the face of limited information.  Most importantly, Julie French’s unwavering 
faith and understanding in me formed the cornerstone of my strength without which my 
studies would have crumbled.   
 
  
vii 
 
Table of Contents 
Chapter 1:  Methods for the Elucidation of Protein-Small Molecule Interactions ............. 1 
1.1 Introduction ............................................................................................................ 2 
1.2 Small molecule-to-protein ...................................................................................... 3 
1.2.1 Small-molecule affinity methods ...................................................................... 3 
1.2.1 Proteomic target identification ......................................................................... 7 
1.2.1 Chemoproteomic target identification ............................................................ 12 
1.3 Protein-to-small molecule .................................................................................... 16 
1.3.1 Biophysical identification of small molecule binders ...................................... 16 
1.3.2 Affinity-based identification of small molecule binders .................................. 18 
1.4 Conclusions ......................................................................................................... 23 
1.5 References .......................................................................................................... 24 
Chapter 2:  Cholesterol is a Natural ERRα Ligand ........................................................ 28 
2.1 Introduction .......................................................................................................... 29 
2.2 Discovery of an endogenous ERRα Binder ......................................................... 30 
2.3 Structural Analysis of ERRα Cholesterol Binding ................................................ 36 
2.4 Cholesterol regulates ERRα Transcription ........................................................... 38 
2.5 Cholesterol regulates ERRα activity in Osteoclastogenesis ................................ 39 
2.6 Cholesterol agonism reveals a novel role for ERRα in atherosclerotic foam cell 
formation .................................................................................................................... 44 
2.7 Cholesterol functions as an ERRα agonist in vivo ............................................... 45 
2.8 Conclusion ........................................................................................................... 48 
2.9 Methods ............................................................................................................... 49 
2.10 References ........................................................................................................ 56 
Chapter 3: Discovery and Characterization of sORF Encoded Peptides....................... 59 
3.1 Introduction .......................................................................................................... 60 
3.2 Discovering SEPs Encoded by Annotated Transcripts ........................................ 62 
3.3 SEPs are Derived from Unannotated Transcripts ................................................ 66 
3.4 SEP Translation is Initiated at Non-AUG Codons ................................................ 68 
3.5 Supporting SEP length assignments ................................................................... 69 
3.6 Cellular Concentrations of SEPs.......................................................................... 71 
3.7 Heterologous Expression of SEPs ....................................................................... 72 
3.8 SEPs Exhibit Subcellular Localization ................................................................. 75 
3.9 Non-AUG Start Codons Enable Bicistronic Expression ....................................... 77 
viii 
 
3.10 A Small Subset of lincRNAs encode SEPs ........................................................ 79 
3.11 Conclusion ......................................................................................................... 80 
3.12 Methods ............................................................................................................. 81 
3.13 References ........................................................................................................ 89 
Chapter 4: Chemoproteomic Discovery of Cysteine Containing Human sORFs ........... 94 
4.1 Introduction .......................................................................................................... 95 
4.2 Isolation of Cysteine Containing SEPs ................................................................ 96 
4.3 Validation of Cysteine SEP Labeling ................................................................... 99 
4.4 Novel ccSEPs .................................................................................................... 101 
Figure 4.3: ccSEP overview. .................................................................................... 102 
4.5 Conclusion ......................................................................................................... 103 
4.6 Methods ............................................................................................................. 104 
4.7 References ........................................................................................................ 109 
Chapter 5:  Functional Characterization of sORF-Encoded Peptides ......................... 110 
5.1 Introduction ........................................................................................................ 111 
5.2  SEPs alter gene expression ............................................................................. 113 
5.3 SEPs can be assigned to putative cellular processes ........................................ 120 
5.4 eIF5-SEP is involved in inflammation ................................................................ 122 
5.5 eIF5-SEP regulation .......................................................................................... 128 
5.6 Conclusion ......................................................................................................... 130 
5.6 Methods: ............................................................................................................ 132 
5.7 References ........................................................................................................ 135 
Appendix: .................................................................................................................... 139 
A.1 Experiments to identify bioactive lipids in cancer and inflammation .................. 139 
A.1.1 Discovery of osteoclast secreted lipids that promote bone cancer metastasis.
 ............................................................................................................................. 139 
A.1.2 Identification of abnormal lipids levels in alopecia inducing mouse milk ..... 140 
A.2 Works Cited ....................................................................................................... 151 
 
  
ix 
 
List of Figures 
 
Figure 1.1.  Affinity capture coupled to SILAC for small molecule target identification .... 5 
Figure 1.2. Drug Affinity Responsive Target Stability (DARTS). ...................................... 9 
Figure 1.3. Stability of Proteins From Rates of Oxidation (SPROX) .............................. 11 
Figure 1.4:  Identifying protein targets in cell culture. .................................................... 15 
Figure 1.5: Thermostability Shift Assay ......................................................................... 18 
Figure 1.6. Affinity methods for elucidating PMIs. ......................................................... 21 
Figure 2.1:  Metabolomics approach to identify ERRα binders. ..................................... 31 
Figure 2.2: ERRα binds to cholesterol ........................................................................... 32 
Figure 2.3:  Diethylstilbestrol blocks ERRα cholesterol binding ..................................... 34 
Figure 2.4: Cholesterol alters ERRα-LBD conformation ................................................ 35 
Figure 2.5: Cholesterol binds ERRα with high affinity ................................................... 36 
Figure 2.6: Cholesterol binds in the ligand binding pocket of ERRα .............................. 37 
Figure 2.7: Cholesterol is an ERRα agonist .................................................................. 39 
Figure 2.8: Cholesterol regulates osteoclastogenesis markers through ERRα ............. 41 
Figure 2.9 Cholesterol regulates osteoclastogenesis in the presence of ERRα: ........... 43 
Figure 2.10  Cholesterol regulates inflammation in an ERRα dependent manner ......... 45 
Figure 2.11:  ERRα mediates cholesterol function in vivo. ............................................ 47 
Figure 3.1 Workflow for identifying short ORF encoded peptides (SEPs). .................... 62 
Figure 3.2: SEP MS/MS Criteria and Spectra ............................................................... 64 
Figure 3.3: Overview of SEPs ....................................................................................... 65 
Figure 3.4:  Conservation of sORFs .............................................................................. 68 
Figure 3.5:  Isotope dilution mass spectrometry (IDMS) of full length deuterated and 
endogenous SEPs......................................................................................................... 71 
Figure 3.6: SEP quantification ....................................................................................... 72 
Figure 3.7 Expression of SEPs from their endogenous RNAs ...................................... 73 
Figure 3.8: Validation of SEP expression ...................................................................... 74 
Figure 3.9:  DEDD2 has truncated transcript variants ................................................... 75 
Figure 3.10:  H2AFx SEP is cytoplasmic ....................................................................... 76 
Figure 3.11: DEDD2-SEP localizes to the mitochondria ................................................ 76 
Figure 3.12: FRAT2 ACG misprimes for methionine ..................................................... 77 
Figure 3.13  FRAT2 mRNA is bicistronic. ...................................................................... 78 
Figure 4.1:  Workflow for identifying ccSEPs ................................................................. 97 
x 
 
Figure 4.2:  Validation of site of labeling and cellular expression of newly discovered 
ccSEPs. ....................................................................................................................... 100 
Figure 5.1:  Platform for functionally characterizing SEPs ........................................... 113 
Figure 5.2:  Signal strength and repeatability of gene expression changes induced by 
SEPs ........................................................................................................................... 117 
Figure 5.3:  Marker analysis indicates SEPs induce specific gene expression changes
 .................................................................................................................................... 118 
Fig 5.4:  Gene set enrichment analysis indicates SEPs induce specific gene expression 
changes ....................................................................................................................... 119 
Figure 5.5:  SEPs are involved in cellular pathways .................................................... 121 
Figure 5.6:  QPCR validates eIF5-SEP gene expression changes ............................. 122 
Figure 5.7  eIF5-SEP induces expression of pro-inflammatory genes ........................ 124 
Figure 5.8:  eIF5-SEP induces expression of IL-8 ....................................................... 125 
Figure 5.9:  IL-8 RNA expression ................................................................................ 126 
Figure 5.10:  eIF5-SEP upregulates pro-inflammatory metabolites ............................. 127 
Figure 5.11:  RACE PCR illustrates a mechanism of EIF5, EIF5-SEP translation ...... 129 
Figure A.1:  Lipids up or down regulated in rosiglitazone treated or control osteoclast.
 .................................................................................................................................... 140 
Figure A.2:  LysoPCs are downregulated in the milk of adiponectin KO mice ............. 141 
Figure A.3:  Triglyceride levles in adiponectin KO and TG mouse milk ....................... 142 
 
 
 
  
xi 
 
List of Tables 
 
Table 2.1 MRM sterol analysis global profiling gradient. ............................................... 52 
Table 2.2:  MRM mass spectrometry method for the targeted identification of sterols. . 53 
Table 4.1:  Detected peptides and the start codon and length ...................................... 99 
Table A.1:  Complete list of SEP detected peptides and validation methods used to 
confirm them from chapter 3. ...................................................................................... 143 
Table A.2: Complete list of detected peptides from SEPs identified in chapter 3 along 
with other detected peptides that map to the same SEP ............................................. 146 
Table A.3:  List of detected peptides from SEPs identified in chapter 3 along with start 
codons, SEP length and Chromosome coordinates. ................................................... 149 
 
 
 
 
 
 
 
 
 
 
  
1 
 
 
 
 
 
 
 
 
Chapter 1:  Methods for the Elucidation of Protein-Small Molecule 
Interactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was adapted from: 
 McFedries A*, Schwaid A*, Saghatelian A. Methods for the Elucidation of Protein-Small 
Molecule Interactions.  Chemistry and Biology, 2013, 20 (5), pp 667-673 
*authors contributed equally. 
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1.1 Introduction 
 
 Understanding the interactions between small molecules and proteins can be 
approached from different perspectives and is important for the advancement of basic 
science and drug development. Chemists often use bioactive small molecules, such as 
natural products or synthetic compounds, as probes to identify therapeutically relevant 
protein targets. Biochemists and biologists often begin with a specific protein and seek 
to identify the endogenous metabolites that bind to it. These interests have led to the 
development of methodology that relies heavily on synthetic and analytical chemistry to 
identify protein-small molecule (PSMIs) and protein-metabolite interactions (PMIs). 
Here, we survey these strategies, highlighting key findings, to demonstrate the value of 
these approaches in answering important chemical and biological questions.    
            A number of different types of molecular interactions enable life. These include 
the interactions between proteins, proteins and nucleic acids, and proteins and small 
molecules. Elucidating these interactions and understanding how they control biology is 
a major scientific goal. A number of approaches have been developed in recent years to 
identify protein-protein interactions 1-6 and protein-nucleic acid interactions 7-9. 
Ribosome profiling, for example, elucidates interactions between the ribosome and RNA 
in cells to reveal novel sites of protein translation. While many methods exist for the 
characterization of biopolymer interactions, far fewer approaches exist to elucidate 
interactions between proteins and small molecules. In recent years, however, more of 
these methods are beginning to emerge.  
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            The importance of protein-small molecule interactions (PSMIs) in drug discovery 
and protein-metabolite interactions (PMIs) in biology has driven the development of new 
methods that rely heavily on the integration of both synthetic chemistry and analytical 
chemistry. Here, we divide these methods into two categories: small molecule-to-protein 
and protein-to-small molecule strategies. This division separates problems that aim to 
identify the protein targets of a bioactive small molecule from problems focused on 
identifying the small molecule-binding partner of a suspected metabolite-binding protein.  
 
1.2 Small molecule-to-protein 
 
1.2.1 Small-molecule affinity methods  
 
One of the successes in using small molecules as affinity reagents is the 
identification of FKBP by the natural product FK506 10. This seminal work led to the 
discovery of new proteins and pathways that explained the mechanism of action of a 
potent class of immunosuppressant drugs 11. In doing so, this work informed us about 
vital, but previously unknown, cellular pathways involved in the regulation of the cellular 
immune response. More generally, these studies highlighted the tremendous value of 
using bioactive small molecules to study biology. Other important examples, including 
the discovery of the histone deactylase family with trapoxin 12, reinforced the impact of 
chemistry in important biological discoveries, leading to the development of the field of 
chemical biology 13. All of this is predicated on being able to use complex bioactive 
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small molecules as affinity reagents, which often requires complex chemical syntheses 
and emphasizes the importance of organic chemistry in this problem.  
The increased use of small molecule screening approaches in biology has led to 
the identification of many bioactive molecules, leading to an increased demand for 
methods that can elucidate PSMIs. Affinity-based methods are still the most common 
approach used and leading methods have learned to integrate these approaches with 
modern proteomics to accelerate targeted discovery. Ong and colleagues, for example, 
have combined small molecule-affinity chromatography with SILAC, a quantitative mass 
spectrometry (MS)-based proteomics strategy, to identify PSMIs on a proteome-wide 
scale 14,15 (Figure 1.1). To demonstrate the generality of this approach seven different 
compounds, including kinase inhibitors and immunophilin ligands, were studied in this 
first example. Derivatives of each of these compounds were prepared and linked to 
solid support by a carbamate linkage, affording small molecule derivatized beads. 
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Figure 1.1.  Affinity capture coupled to SILAC for small molecule target 
identification. Cells are grown in ‘heavy’ or ‘light’ media and subsequently lysed. 
These ‘heavy’ and ‘light’ cell lysates are separately incubated with beads that are 
modified with a small molecule of interest.  Excess small molecule is added to the 
‘light’ cell lysate and this soluble small molecule prevents any specific small molecule-
protein interactions with the beads. After removal of the lysate bound proteins are 
eluted from the beads and the lysates are then combined for subsequent analysis 
using quantitative proteomics. The samples can be distinguished by mass 
spectrometry since proteins from each sample have different molecular weights, and 
therefore specific PMSIs can be identified by the higher concentrations of these 
‘heavy’ proteins versus ‘light’ proteins.     
 
6 
 
 In SILAC, cells are then grown in regular media (light) or specialized media 
(heavy) that replaces certain amino acids with stable isotope labeled derivatives (e.g. 
13C6-arginine and 13C6,15N2-lysine). The result is that the proteins in the ‘heavy’ cells 
have proteins that weigh more than the exact same proteins in ‘light’ cells, and these 
proteins can be distinguished and quantified by mass spectrometry. SILAC is used to 
identify PSMIs by passing ‘light’ lysate over beads coated with the bioactive small 
molecule. Any proteins with affinity for the small molecule are retained. As a control, a 
soluble variant of the small molecule is added to the ‘heavy’ lysate before it is incubated 
with the small molecule-modified beads. This soluble compound has the effect of 
binding of target proteins and preventing their binding to the small molecules on the 
surface of the bead. The post-bead lysate samples are then combined and analyzed by 
mass spectrometry. The ratio of light-to-heavy can identify those proteins that are 
specifically enriched by the small molecule on the bead, and therefore identify any 
target proteins of the small molecule.  
The results from these initial experiments were excellent. All the compounds 
used identified known PSMIs, and several revealed some novel interactions. Moreover, 
by using compounds with different affinities for their targets, this work demonstrated that 
this method can successfully identify PSMIs with affinities from the low nanomolar (26 
nM) to micromolar (44 µM) range. This strategy has been applied to the identification of 
the primary targets of piperlongumine 16, a compound that was shown to selectively kill 
cancer cells in vitro and in vivo by targeting the stress response to reactive oxygen 
species (ROS) 17. Overall, these types of affinity approaches have come to dominate 
the methods that are used to identify PMSIs. Examples include the identification of the 
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nucleophosmin as a target of natural product avrainvillamide 18, the finding that 
cephalostatin A binds to specifically to members of the oxysterol binding-proteins, in the 
process revealing these proteins to be important in cancer cell proliferation19.  
Importantly, affinity methods are not limited to synthetic compounds or natural 
products, but can also be used with endogenous metabolites. Specifically, Nachtergaele 
and colleagues demonstrated a direct binding interaction between 20(S)-
hydroxycholesterol and the oncoprotein smoothened (Smo), a key protein in the sonic 
hedgehog (Shh) pathway, using a derivative of 20(S)-hydroxycholesterol (nat-20(S)-
yne) that was immobilized onto a solid support using Sharpless’ click chemistry 20. This 
example highlights the generality of affinity based approaches in identifying PSMIs. The 
only limitation appears to be the ability to access derivatives for immobilization by 
chemical synthesis that retain high affinity for their protein target. As scientists continue 
to gain interest in understanding the mechanism underlying bioactive small molecules, 
affinity-based methods will continue to be applied to many more target molecules.  
 
1.2.1 Proteomic target identification  
 
In cases where small molecules are difficult to modify, or the synthetic skill 
necessary to make such modifications are difficult to access, a new group of powerful 
proteomics methods to discover novel PSMIs can be used. These strategies rely on 
detecting differences in the stability between unbound and small-molecule bound 
proteins to identify the target(s) of a small molecule. Drug affinity responsive target 
stability (DARTS) is one such method 21. DARTS relies on the fact that proteins are 
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more stable when bound to a metabolite, which makes them less susceptible to 
proteolysis. By comparing lysates with and without a small molecule in the presence of 
protease the small-molecule protein target(s) can be identified as the protein(s) that are 
more stable in the presence of the small molecule (Figure 1.2). Proof-of-concept 
experiments revealed that mammalian target of rapamycin (mTOR), for example, is less 
susceptible to proteolysis in the presence of E4, an mTOR kinase inhibitor. Moreover, 
DARTS is generally applicable and was used with other enzyme-inhibitor pairs, such as 
the COX2-celecoxib pair.  
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 Next, DARTS was used to characterize PSMIs for resveratrol, an anti-aging 
compound thought to act primarily through interactions with the sirtuin protein Sirt1. 
 
Figure 1.2. Drug Affinity Responsive Target Stability (DARTS). Aliquots of a 
protein lysate are mixed with either a small molecule (+ ligand) or solvent control 
(-ligand) to identify PSMIs. These samples are then subjected to limited 
proteolysis and compared by gel electrophoresis and quantitative mass 
spectrometry. Protein targets are identified as those proteins that display show 
increased protease resistance in the presence of the small molecule.  
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Using a yeast and human lysates the authors discovered that eukaroyotic initiation 
factor A (eIF4A) is a target of resveratrol, which demonstrates that DARTS is able to 
discover novel PSMIs. Importantly, the authors confirmed that at least some of the 
biology controlled by resveratrol is eIF4A dependent because worms lacking eIF4A no 
longer show any anti-aging in the presence of resveratrol. Together these experiments 
demonstrate the value and utility of DARTS for discovering PSMIs.  
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 Most recently, a proteomics method called Stability of Proteins from Rates of 
Oxidation (SPROX) was developed to identify PSMIs in complex cell lysates 22-25. 
Rather than relying on non-specific proteolysis, which can make downstream mass 
spectrometry experiments difficult to interpret, SPROX relies on the irreversible 
oxidation of methionine residues by hydrogen peroxide to report on the thermodynamic 
stability of a protein’s structure during chemical denaturation (Figure 1.3). Proof-of-
 
 
Figure 1.3. Stability of Proteins From Rates of Oxidation (SPROX). SPROx Identifies the 
targets of a small molecule from a complex protein mixture by measuring the ligand-induced 
changes in the rate of methionine amino acid side chain oxidation by hydrogen peroxide. 
Aliquots of the cell lysate are incubated with either a small molecule or a solvent control, then 
incubated with increasing concentrations of guanidine hydrocholride. 
Ligand induced difference in target protein unfolding will impact the rate of selective methione 
oxidation by hydrogen peroxide. Quantitative proteomic is used to compare levels 
of nonoxidized versus oxidized methionine-containing peptides in each sample set (small 
molecule versus control) to determine the rate of target protein oxidation as a function 
of guanidine hydrocholride concentration. A shift of the transition midpoint for a protein 
between +ligand and –ligand samples indicates that the protein is a target for the small 
molecule in lysate.   
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concept SPROX experiments performed using yeast lysates validated this approach by 
identifying  known binders of the immunosuppressant drug cyclosporine A (CsA)  23.  
SPROX has also been used with resveratrol, identifying the known target cytosolic 
aldehyde dehydrogenase, along with several novel interactions 25.  SPROX requires 
that target proteins contain methionine residues, and MudPIT analysis of SPROX 
experiments using yeast lysates demonstrated that 33% of the detectable proteins 
contain a methionine.     
A SPROX-like method that uses s-methyl thioacetimidate (SMTA) labeling to 
detect amidination difference of proteins and protein-ligand complexes during chemical 
denaturation has also been explored 26. This method requires target proteins to contain 
lysine residues or have a buried N-terminus in the native state. This method is 
particularly useful when a ligand of interest is not stable in hydrogen peroxide and 
therefore cannot be investigated by SPROX. SMTA labeling and SPROX complement 
each other, covering a wider range of the proteome 26. Studying the thermodynamic 
stability of proteins under denaturing conditions in the presence and absence of ligand 
is an effective protein target identification strategy. However, the two described 
approaches require relatively larger concentrations of ligand, in the uM to mM range, 
but provide the flexibility to be used with a variety of downstream quantitative proteomic 
analysis.   
 
  
1.2.1 Chemoproteomic target identification 
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 Unfortunately, not all proteins are as active in lysates as they are within the 
context of a cell, and therefore some relevant PSMIs or PMIs may be missed when 
using lysates. Screening a spiroepoxide library for antiproliferative compounds, for 
example, revealed that the most relevant biological target of the active spiroepoxide is 
only targeted in a living cell, but was inactive once the cell was lysed 27. Many molecular 
mechanisms can account for the difference between intact cells and lysates but the 
ultimate point is that it is difficult to exactly replicate cellular conditions in any type of 
biochemical experiment. Since it is impossible to predict what PSMIs are sensitive to 
cellular conditions new chemoproteomic approaches have been developed to enable 
target identification within live cells.  
These methods rely on the use of small molecules that can covalently label their 
protein targets so that intracellular labeling events can be detected after cell lysis. 
Manabe and colleagues demonstrated the value of this approach with a modified 
natural product derivative in an effort to identify its protein target 28. Potassium 
isolespedezate, a metabolite known to induce nyctinastic leaf opening in the motor cells 
of plants belonging to the Cassia genus, was derivitized with an iodoacetamide for 
covalent crosslinking to its target and an azide to enable enrichment and identification of 
the isolespedezate target by conjugation to a flag peptide using click chemistry. This 
approach led to the identification of 5-methyltetrahydropteroyltriglutamate-homocysteine 
S-methyltransferase (MetE) as the isolespedezate target protein. This method, while 
powerful, is mostly limited by the ability to synthesize natural product derivatives that 
can covalently label their target while maintaining the potency of the compound.  
14 
 
 Most recently, a chemoproteomic strategy approach was developed for the 
identification of PMIs for the endogenous metabolite cholesterol. Cholesterol is a central 
metabolite with roles in membrane structure, metabolism, signaling and disease. While 
many important functions of this molecule are known, the full spectrum of proteins that 
interact with cholesterol is far from complete. Hulce and coworkers synthesized a series 
of cholesterol derivatives, and controls, containing a photocrosslinking diazirine group 29 
(Figure 4). In practice, cells are irradiated by light after exposure to these sterol probes 
resulting in the covalent modification of any protein they bind. Addition of exogenous 
cholesterol blocks the overall labeling of these probes to validate that binding of these 
probes is occurring at cholesterol-specific binding sites.  Subsequent to probe labeling, 
the probe is conjugated to biotin by CuACC chemistry allowing for affinity purification of 
labeled proteins.  
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Figure 1.4:  Identifying protein targets in cell culture. Cells grown in ‘heavy’ and 
‘light’ media are treated with a cholesterol probe compound that has been modified to 
contain a diazirine moiety. In addition, excess cholesterol is also added to the ‘light’ 
sample and this will act to compete any specific cholesterol probe–protein interactions. 
The cholesterol probe is photocrosslinked to any bound protein targets in cells, and 
the cells are subsequently lysed. Any cholesterol probe–protein conjugates in this 
lysate are then modified with biotin using ‘click’ chemistry and labeled proteins are 
separated from cell lysate by affinity chromatography. The ‘heavy’ and ‘light’ fractions 
are then mixed and examined by quantitative proteomics. Proteins that specifically 
bind cholesterol will have a higher ratio of ‘heavy’ to ‘light’ in the mass spectrum. 
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 Integrating these sterol probes with SILAC enables the identification of sterol 
probe-target proteins. In these experiments, the probe is added to both ‘heavy’ and 
‘light’ cells, but the ‘light’ cells also contain a competitor (cholesterol) to block binding. 
Subsequent analysis of the ‘heavy’ and ‘light’ samples identifies cholesterol-binding 
proteins as those proteins enriched in the heavy sample versus the control sample. The 
identification of several known cholesterol-binding proteins such as Scap, caveolin and 
HMG-CoA reductase validated the methodology. Subsequent analysis of the entire data 
set using various bioinformatics tools revealed that almost every major class of protein 
has members that bind cholesterol, including GPCRs, ion channels and enzymes. More 
broadly, the analysis also revealed an enrichment of proteins involved in neurological 
disorders, cardiovascular and metabolic disease, demonstrating the potential 
therapeutic insights that may eventually be provided by this data.   
Together these examples demonstrate the utility of chemoproteomic approaches 
to identify PSMIs and PMIs, and highlight the power of these approaches to rapidly 
increase our understanding of the role of specific small molecules in biology.    
 
1.3 Protein-to-small molecule 
 
1.3.1 Biophysical identification of small molecule binders  
 
 In many cases, the problem of identifying a PMI begins with interest in a 
particular protein. This protein may be a potential drug target or it may be suspected to 
require small molecule binding to regulate its activity. There are numerous cell-based 
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assays for GPCRs, nuclear receptors, enzymes and many more proteins that are 
routinely used to identify new small molecule ligands. In general, these methods are 
highly effective. Such assays have already been reviewed extensively in the literature. 
Instead, this chapter focuses on cell-free approaches that rely heavily on biochemical, 
biophysical and profiling methods to reveal PMIs for endogenous metabolites.  
Biophysical screening methods provide an effective means for PMI discovery 
from endogenous metabolites. Differential scanning techniques were originally 
developed to optimize recombinant protein stability (i.e. melting temperature (Tm)) for 
purification and crystallography 30. Differential static light scattering (DSLS) and/or 
differential scanning fluorometry (DSF) are the two most commonly used methods. 
DSLS measured denaturation by tracking temperature induced increases in the intensity 
of scattered light, while DSF measured increases in the fluorescence from the 
environmentally sensitive dye SYPRO Orange. Shifts in melting temperatures of > 2 °C 
were found to confidently represent binding events and conditions that enhanced 
protein stability, and thermal shifts > 4 °C increased the likelihood of positive results in 
crystallographic screens. 
These methods have recently been extended to identify PMIs by measuring the 
effect of small molecules on the melting temperature (Tm) of proteins. The binding 
between a small molecule and protein stabilizes the protein structure (i.e. raises the Tm) 
(Figure 1.5).  Recently, DeSantis and coworkers used DSF to identify natural estrogen 
receptor alpha (ERα) from a library of molecules 31.  DSF successfully identified known 
natural ERα agonists, β-estradiol and estrone, demonstrating the utility of this assay in 
characterizing natural PMIs. The authors suggest that these assays will be useful in the 
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identification of unknown nuclear receptor ligands in the future.
 
1.3.2 Affinity-based identification of small molecule binders  
 
         Alternatively, affinity based experiments using immobilized proteins are another 
option for the characterization of PMIs.  In general, these assays provide the advantage 
that they can be performed with unmodified metabolite resulting in a reduced likelihood 
of false negatives.  This approach relies on the fact that proteins can be immobilized 
without altering the secondary structure of the protein or interfering with ligand binding. 
The first examples of affinity methods relied on using radioisotopes to identify PMIs by 
         
 
Figure 1.5: Thermostability Shift Assay. PSMI and PMIs can be identified in a 
high-throughput fashion by monitoring shifts in the melting temperature (Tm) of a 
protein-ligand complex versus a protein-solvent control. The environmentally 
sensitive dye SYPRO Orange emits when bound to hydrophobic amino acid 
residues and is used to monitor protein unfolding via differential scanning 
fluorimetry (DSF). 
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measuring radioactivity of a protein after incubation and washing with a radiolabeled 
ligand 32,33.  
Most recently, this approach has been optimized in the form of a DRaCALA 
assay (Differential radial capillary action of ligand assay), which allows for the rapid high 
throughput identification of PMIs using radiolabelled metabolites 34. DRaCALA utilizes 
the affinity of proteins for nitrocellulose membranes to sequester radiolabelled 
metabolites bound to protein.  A solution containing the protein of interest and 
radiolabelled ligand is spotted on nitrocellulose.  Unbound ligand will diffuse with the 
solvent throughout the membrane, whereas protein and ligand bound to protein will be 
immobilized at the point it was spotted. One advantage of DRaCALA is that it can be 
performed using whole cell lysates to identify PMIs, which avoids time-consuming 
protein purification.  
The one disadvantage of this method is that it requires foreknowledge as to what 
candidate metabolites should be tested, and in that each metabolite must be tested 
individually. Nevertheless, for certain cases DRaCALA  provides a high-throughput 
means to identify ligand-binding proteins. The identification of prokaryotes that have the 
proteins capable of binding bis-(3’-5’)-cyclic dimeric guanosine monophosphate 
(cdiGMP), a metabolite important in biofilm formation, was accomplished by simply 
using lysates from 191 strains of P. aeruginosa and 82 other bacterial strains. The ‘hits’ 
in this assay corresponded to those bacteria that have diguanylate cyclase (DGC), as 
expected. This approach precludes the identification of unexpected PMIs or PMIs with 
novel metabolites.  Still, DRaCALA remains a powerful approach for uncovering protein 
metabolite interactions.  
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 The use of global mass spectrometry approaches allows for the scrutiny of a 
larger pool of metabolites, including novel metabolites, and can result in the unbiased 
identification of protein metabolite binding. Specifically, the use of global metabolite 
profiling enabled the development of a novel, unbiased, strategy for the identification of 
endogenous PMIs 35 (Figure 1.6). In this approach, recombinant proteins fused to an 
affinity tag—either GST or hexahistidine—are immobilized on a solid support. 
Incubation of these proteins with a metabolite mixture, typically an extract containing the 
entire lipidome from a cell or tissue of interest results in the formation of a protein-
metabolite complex on the bead. Following this incubation, the protein is washed, 
subsequently eluted from the solid support, and the eluant is then analyzed using a 
liquid chromatography–mass spectrometry (LC–MS) metabolite profiling platform. 
Quantitative comparison of the metabolite profiles between samples with and without 
protein reveals any metabolites that are enriched by the protein. 
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         This approach was developed using three different lipid binding proteins with 
known ligands: cytosolic retinoic acid binding protein 2 (CRABP2), fatty acid binding 
protein 2 (FABP2) and StarD3. The strategy successfully identified specific PMIs for all 
three of these proteins, and in doing so created a reliable method to pulldown protein 
 
Figure 1.6. Affinity methods for elucidating PMIs. A) Protein (blue) is immobilized 
on a solid support (grey) and incubated with lipids from tissue lysate. The immobilized 
protein is then washed and the protein is eluted from the beads. The eluate is then 
analyzed by LC-MS and compared to eluate from a control sample (solid support with 
no protein) by in order to identify specific PMIs. B) A yeast strain bearing either the 
protein of interest fused to an IgG epitope tag, or the IgG epitope tag only, were lysed 
and immunoprecipitated using antibody labeled beads.  Lipids were then extracted 
from the beads and examined by LC-MS.  Comparison between the protein and 
control sample can be used to identify any specific PMIs. 
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metabolite interactions 35.  It does not require any explicit knowledge about the identity 
of the metabolite and can be conducted rapidly against a large pool of metabolites.  
Moreover, it was not susceptible to the enrichment of nonspecific metabolites.  Although 
the examples presented here centered around lipids, there is no reason this approach 
could not be used for polar metabolites as well. This strategy has been successfully 
applied to other PMIs, including the discovery that arachidonic acid and 
docosahexanoic acid, polyunsaturated fatty acids, bind to the orphan nuclear receptor 
Nur77 36.   
Li and colleagues developed an exciting strategy to identify PMIs within yeast 37 
(Figure 1.6). Specifically, they focused on interaction with yeast protein kinsases as well 
as proteins that comprise ergosterol pathway. The proteins in this group were epitope 
tagged to enable their immunoprecipitation from cellular lysates. These 
immunoprecipitated samples were analyzed by metabolomics to identify any 
endogenous metabolites bound to the proteins. As a control, each sample was also 
checked by SDS-PAGE to ensure pulldown of the target protein was successful.  
Comparison of the metabolite profiles from these various samples revealed a 
number of new interactions. Many of the enzymes within the ergosterol pathway bound 
to sterol intermediates, which suggest that these molecules exert regulation on the 
pathway. Interestingly, it was also discovered that some of the proteins within the 
ergosterol pathway bind to pentaporphoryin, which was a complete surprise but helps 
explain a previous observation linking pentaporphoryin and ergosterol regulation. 
Furthermore, their analysis led to the discovery that a number of yeast protein kinases 
are regulated by ergosterol highlighting the generality of this method towards numerous 
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protein classes. In aggregate, this data highlights the potential for unbiased PMI 
identification to greatly increase our current understanding of endogenous small 
molecule biology.  
 
 
1.4 Conclusions 
 
A successful library of approaches to determine PSMIs and PMIs has been 
developed, and is ready to be applied to identify unknown PMIs of interest. These 
approaches enable the discovery of novel interactions and are also designed to 
maximize the likelihood that the interactions are occurring in cells and tissues. The 
continued application of these methods will enrich our understanding of small molecule 
biology and also stimulate the development of improved methods for discovering these 
interactions. As demonstrated by the above examples this research area sits squarely 
at the interface of chemistry and biology and will greatly benefit from collaboration 
between future generations of chemists, biochemists, and biologists.  
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2.1 Introduction 
 
 Estrogen-related receptors are a family of orphan nuclear receptors that consist 
of ERRα, ERRβ and ERRγ1,2. Through their regulation of transcription, these proteins 
control a variety of physiological and pathological pathways. ERRα is the most studied 
member of this nuclear receptor subgroup, yet has eluded deorphanization for over a 
quarter of a century. ERRα is a critical regulator of bone remodeling by controlling key 
bone cell differentiation processes such as osteoclastogenesis; ERRα deletion 
attenuates osteoclast differentiation and bone resorption leading to increased bone 
mass3. ERRα also modulates energy metabolism by controlling adipogenesis, 
lipogenesis, insulin sensitivity, mitochondria biogenesis and fatty acid oxidation; ERRα 
deletion or inhibition confers resistance to obesity and insulin resistance4-6. 
Furthermore, clinical and basic research has revealed ERRα as an important regulator 
of multiple cancers4,7. Despite the centrality of ERRα in human biology, an endogenous 
ligand for ERRα has been elusive. 
 ERRα was originally identified based on its homology to the estrogen receptor α 
(ERα)2. Analysis of the individual domains reveals that the DNA-binding domains 
(DBDs) of ERRα and ERα are 70% homologous, but their ligand-binding domains 
(LBDs) are only 36% similar. Indeed, while ERα transcriptional activity is regulated by 
17β-estradiol, estrone or estriol binding to its LBD8, these steroid hormones have no 
impact on ERRα function9. Nuclear receptor transcriptional activity is usually regulated 
by metabolite ligands; however ERRα is constitutively active in the absence of an 
exogenous small molecule. Moreover, the ligand-binding pocket of ERRα bound to a co-
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activator peptide is almost completely occluded by hydrophobic residues.  Therefore, 
the current hypothesis is that ERRα is a ligand-independent nuclear receptor10.    
The importance of ERRα biology in human health has led to tremendous interest 
in this protein as a novel therapeutic target. A number of synthetic small-molecule ERRα 
antagonists have been developed. These compounds bind to the ERRα ligand-binding 
pocket and induce a conformational shift in the LBD that interferes with co-activator 
binding and inactivates transcription. ERRα antagonists have been found to induce 
cancer cell death11, inhibit tumor growth12, and improve insulin sensitivity and glucose 
tolerance5. More generally, the discovery of these antagonists indicates that ERRα has 
a functional small-molecule binding pocket, renewing the idea that ERRα has an 
endogenous ligand.  
 
2.2 Discovery of an endogenous ERRα Binder 
 
 The identification of endogenous nuclear receptor ligands is typically 
accomplished using functional screens to identify metabolites that regulate nuclear 
receptor transcriptional activity.  Screening several phospholipids in a transcriptional 
reporter assay, for example, has led to the identification of an endogenous LRH-1 
ligand13. While successful in some cases, cell-based assays with natural metabolites 
have certain drawbacks that could potentially lead to false negatives. Recent work, for 
example, has demonstrated the importance of cellular proteins in the transport14 and 
metabolism15 of endogenous ligands. To obviate the need to consider these variables, 
we decided on an unbiased metabolite profiling strategy to identify an endogenous 
ligand for ERRα.   
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 In this approach, comparative metabolite profiling is used to identify metabolites 
that are specifically enriched from a cellular extract by resin bound ERRα-LBD (Fig. 
2.1). We previously used this method to enrich endogenous PPARγ ligands from cells16, 
indicating the compatibility of this approach with nuclear receptors. Recombinant 
hexahistidine-tagged ERRα-LBD (HIS-ERRα-LBD) was expressed, purified and 
immobilized on a nickel bound resin. Resin loaded with ERRα-LBD was used to enrich 
 
Figure 2.1:  Metabolomics approach to identify ERRα binders.  His-ERRα-LBD 
was immobilized on a solid support, and incubated with lipids from brain or kidney.  
After incubation, unbound lipids were washed away and protein was eluted.  Eluant 
was then analyzed by LC-MS TOF and compared to a no protein control.  
Differences in detected lipids can be attributed to the protein binding. 
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lipids from brain or kidney extracts, which were selected because of the robust 
expression of ERRα in these tissues. Analysis of the metabolite profiling data from this 
experiment compared to a control (unloaded resin) identified cholesterol as the only 
metabolite that was significantly enriched (p<0.05 and >2-fold) by the HIS-ERRα-LBD 
resin, revealing a specific binding interaction between ERRα-LBD and cholesterol 
(Figure 2.2).   
 
Several further experiments were performed to validate this interaction. First, the 
addition of the synthetic ERRα antagonist diethylstilbestrol (DES) to tissue extracts 
inhibited cholesterol enrichment by the HIS-ERRα-LBD resin (Figure 2.3). Metabolite 
profiling of this experiment revealed that HIS-ERRα-LBD enriched DES, implying that 
DES binding prevented cholesterol binding.  Next, the addition of the synthetic ERRα 
 
Figure 2.2: ERRα binds to cholesterol.  (Left)  Using a global lipid pulldown from brain 
lysate, cholesterol was identified as the only statistically enriched binder.  (Right)  In order 
to determine whether cholesterol binding was specific or whether other sterols were 
enriched by ERRα, immobilized ERRα was incubated with sterols from brain or kidney, 
washed, and protein was eluted.  Lipids were analyzed by a targeted MRM method in order 
to sensitively identify ERRα binders.  Again, cholesterol was the only sterol found to bind 
ERRα indicating cholesterol ERRα binding is specific.  This result could be repeated from 
brain or kidney lysate.  Statistics was performed with a Student’s t-test, *, p ≤ 0.05     
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antagonist/inverse agonist XCT790, DES, or cholesterol to the ERRα LBD all resulted in 
a conformational change in the protein whereas the negative control compound 
estradiol did not (Figure 2.4).  Lastly, a tryptophan fluorescence assay indicated that 
cholesterol bound to the HIS-ERRα-LBD with a kD of ~700 nM.  Estradiol had no effect 
on HIS-ERRα-LBD tryptophan fluorescence, indicating specificity in ERRα-cholesterol 
interaction (Figure 2.5). These data validate the existence of a specific and high affinity 
ERRα-cholesterol binding interaction.  
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Figure 2.3:  Diethylstilbestrol blocks ERRα cholesterol binding.  Brain lipids were 
spiked with DES (79uM), and this lipid mixture was incubated with immobilized ERRα.  
After washing eluant was analyzed by mass spectrometry.  DES binding to ERRα was 
observed by LC-MS TOF, and cholesterol binding was blocked in the presence of 
DES.  Statistics was performed with a Student’s t-test, *, p ≤ 0.05 
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Figure 2.4: Cholesterol alters ERRα-LBD conformation.  Cholesterol, and 
synthetic ERRα antagonists alter the conformation of ERRα-LBD as measured by 
circular dichroism.  Estradiol, a ligand known not to bind ERRα, does not alter its 
conformation.  
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2.3 Structural Analysis of ERRα Cholesterol Binding 
 
To gain additional detail into how cholesterol binds ERRα, we probed ERRα binding 
with two different fluorescent cholesterol derivatives, 25-NDB- and 6-NDB-cholesterol. 
While 25-NDB-cholesterol binds HIS-ERRα-LBD, 6-NDB-cholesterol did not (Fig. 2.6). 
The data suggest that cholesterol is oriented with its hydroxyl group facing into the 
ligand-binding pocket. We obtained a more detailed structural model for cholesterol 
binding by computationally docking cholesterol into the ERRα ligand-binding pocket. 
These simulations identified a hydrogen bond between amino acid E331 and the 
cholesterol hydroxyl group (Fig 2.6).  In addition, F328 and L324 also appear to make 
important hydrophobic contacts with cholesterol.  Mutagenesis studies supported this 
model. Mutating E331A, F328A, and L324A left the secondary structure of ERRα intact, 
but prevented cholesterol binding (Fig 2.6).  
 
  
Figure 2.5: Cholesterol binds ERRα with high affinity.  (Left) Intrinsic 
tryptophan fluorescence of ERRalpha upon addition of cholesterol demonstrated 
cholesterol bound with a kD of ~700nM.  (Right) Intrinsic tryptophan fluorescence 
of ERRα does not change upon addition of a negative control sterol, estradiol.   
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Figure 2.6: Cholesterol binds in the ligand binding pocket of ERRα.  (A) Docking 
of cholesterol to the ERRα ligand binding pocket suggests cholesterol has important 
interactions with three amino acids in the ERRα ligand binding pocket, E331, F328, 
and L324.  (B)  An ERRα triple mutant E331A, F328A, and L324A has alpha helical 
secondary structure indicative of proper folding as indicated by circular dichroism.  
(C)  Fluorescence polarization assays demonstrated that cholesterol fluorescently 
labeled at the aliphatic chain, but not at the sterol are able to bind to ERRα indicating 
that cholesterol binds with its hydroxyl end facing into the ligand binding pocket. (D)  
The ERRα E331A F328A L324A triple mutant can no longer bind cholesterol relative 
to the WT protein.  Statistics was performed with a Student’s t-test, *, p ≤ 0.05.  
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2.4 Cholesterol regulates ERRα Transcription 
 
 If cholesterol is a bona fide ERRα ligand, it must demonstrate the ability to 
modulate ERRα transcriptional activity. Conventional luciferase transactivation 
strategies, where a ligand is added to detect an increase in transcriptional activity, are 
complicated by the presence of abundant amounts of endogenous ligands, such as 
cholesterol, already in the media and cells. Rather than introduce cholesterol, we 
decided that a more prudent strategy would be to measure ERRα activity upon 
cholesterol depletion. We lowered intracellular cholesterol levels in three ways: lipid free 
serum, cholesterol-binding cyclodextrans and/or statins. Cyclodextran and statin both 
attenuated ERRα transactivation, and also had a cumulative effect (Fig. 2.7). This data 
indicate that cholesterol levels positively correlate with ERRα activity, which would be 
expected for an ERRα agonist. Importantly, adding back of cholesterol to these samples 
rescued ERRα activity, indicating that cholesterol and not a precursor of the cholesterol 
pathway is involved in ERRα activity (Figure 2.7). These results suggest that cholesterol 
is an endogenous ERRα agonist that promotes ERRα-mediated transcription. 
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2.5 Cholesterol regulates ERRα activity in Osteoclastogenesis 
 
 On the basis of these results, we next investigated whether cholesterol and 
ERRα are functionally dependent. We decided to examine osteoclastogenesis, a key 
cellular differentiation process in the physiological regulation of bone remodeling as well 
as in diseases such as osteoporosis.  Osteoclasts are differentiated from 
monocyte/macrophage precursor cells upon treatment with receptor activator of nuclear 
factor kappa-B ligand (RANKL)17,18. We have recently shown that ERRα promotes 
osteoclast differentiation and activity, as a result, ERRα knockout mice exhibit 
decreased bone resorption and high bone mass19.  Interestingly, both statins and 
nitrogen-containing bisphosphonates suppress osteoclast function; and both inhibit the 
cholesterol synthesis pathways, by blocking the HMG-CoA reductase and farnesyl 
 
 
Figure 2.7: Cholesterol is an ERRα agonist.  Luciferase assays demonstrate that 
upon depletion of cholesterol with lovastatin or HPCD ERRα transactivation is 
attenuated.  Addition of cholesterol to cholesterol depleted cells rescues ERRα 
transactivation. Statistics was performed with a Student’s t-test, *, p ≤ 0.05, **, p≤ 0.01.  
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diphosphate synthase (FPPS), respectively20,21.  However, the molecular target for how 
exactly the cholesterol synthesis pathway impacts osteoclastogenesis is still an open 
question, although interference with protein prenylation by bisphosphonates has been 
suggested21.  
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Figure 2.8: Cholesterol regulates osteoclastogenesis markers through ERRα.  
(Left) Cholesterol addition or depletion regulates osteoclast marker genes in the 
presence but not absence of ERRα.  (Right)  WhenERRα cholesterol binding is 
blocked by addition of a synthetic ERRα antagonist, XCT790, cholesterol does not 
affect osteoclast marker gene levels. 
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 To test the hypothesis that cholesterol, statins and bisphosphonates regulate 
osteoclast differentiation via ERRα, we performed bone marrow osteoclast 
differentiation assays. We found that osteoclastogenesis was strongly dependent on the 
presence or absence of cholesterol. Cholesterol addition enhanced osteoclast 
formation, whereas cholesterol depletion by treatment with zoledronate (a clinically used 
nitrogen-containing bisphosphonates) or lovastatin inhibited osteoclast formation 
(Figure 2.8). Cholesterol adding back to zoledronate- or lovastatin-treated cells was 
able to rescue osteoclast differentiation indicating cholesterol rather than cholesterol 
precursors in the synthesis pathway was responsible for the changes in differentiation 
(Figure 2.8).  Gene expression analysis showed that cholesterol up-regulated the 
expression of both ERRα target genes that stimulate mitochondrial biogenesis and 
osteoclast activity, such as Aco2, IDH3a and VLCAD3, and osteoclast differentiation 
markers such as TRAP (tartrate-resistant acid phosphatase) and Ctsk (Cathepsin K) 
(Figure 2.8).  
 Similar experiments using ERRα null (ERRα -/-) bone marrow osteoclast 
differentiation cultures reveal that the effects of cholesterol on osteoclastogenesis was 
completely abolished by ERRα deletion. In the absence of ERRα, osteoclast 
differentiation was neither enhanced by cholesterol nor suppressed by lovastatin or 
zoledronate (Fig. 3a). Consistent with this observation, cholesterol, lovastatin or 
zoledronate no longer altered the expression of ERRα target genes or osteoclast 
differentiation markers (Fig. 3b). In addition to genetic loss-of-function by ERRα 
deletion, biochemical inhibition with a synthetic ERRα antagonist/inverse agonist 
XCT790 also prevented the effects of cholesterol on WT osteoclast differentiation 
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cultures (Fig. 3c). These data indicate that cholesterol enhances osteoclastogenesis in 
an ERRα-dependent manner.  In conjunction with biochemical data demonstrating 
cholesterol binding to ERRα-LBD and cellular reporter assays demonstrating cholesterol 
stimulation of ERRα transcriptional activity, these results suggest that cholesterol 
promotes osteoclastogenesis by functioning as an ERRα agonist, whereas statins and 
bisphosphonates suppress osteoclastogenesis by reducing the bioavailability of the 
endogenous ERRα agonist cholesterol.    
 
 
 
 
Figure 2.9 Cholesterol regulates osteoclastogenesis in the presence of ERRα:  
Cholesterol addition or depletion with statins or bisphosphonates regulated 
osteoclastogenesis in macrophages (Left), but not in ERRα knockout macrophages 
(right).  Osteoclasts are the large pink cells.  Undifferentiated macrophages are the 
smaller pink dots.   
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2.6 Cholesterol agonism reveals a novel role for ERRα in atherosclerotic foam cell 
formation 
 
 We next investigated whether the recently reported anti-inflammatory role of 
cholesterol in macrophages was also ERRα-dependent, to further examine the 
functional association between ERRα and cholesterol in a different biological context. 
Cholesterol has been shown to inhibit macrophage expression of cytokines Cxcl9 and 
Cxcl1022. We found that LPS-induced Cxcl9 and Cxcl10 expression was suppressed by 
cholesterol and exacerbated by lovastatin or zoledronate in WT macrophages. In 
contrast, these effects were once again abolished in ERRα-/- macrophages (Figure 
2.10). Furthermore, cholesterol inhibition of Cxcl9 and Cxcl10 expression was also 
absent in macrophages treated with XCT790. These data not only indicate that the 
cytokine-suppressive effect of cholesterol in macrophages is ERRα-mediated but also 
reveal a novel anti-inflammatory role for ERRα. Importantly, these results provide further 
evidence that cholesterol is a functional ERRα agonist in another biological process. 
  
45 
 
 
2.7 Cholesterol functions as an ERRα agonist in vivo 
 
 To gain insight to whether the functional relationship between cholesterol and 
ERRα extends to physiology and pharmacology, we next performed in vivo studies in the 
context of bone resorption and skeletal remodeling. Epidemiological and pharmacological 
studies in human show that cholesterol-lowering drugs such as bisphosphonates and 
statins are bone protective14, whereas hypercholesterolemia is associated with bone 
loss20,21. As a loss-of-cholesterol-function approach, we treated WT or ERRα-/- mice with 
zoledronate, which targets bone more efficiently than statins, and compared them to 
vehicle-treated mice 4 weeks later. ELISA analyses showed that zoledronate significantly 
 
Figure 2.10  Cholesterol regulates inflammation in an ERRα dependent manner.  
Addition or depletion regulates mRNA levels of markers involved atherosclertoic 
inflammation in macrophages.  However, this effect is dependent on ERRα, and 
cholesterol does not affect inflammation in the absence of ERRα.  Likewise, the 
effects of cholesterol are blocked when cholesterol ERRα binding is blocked by 
addition of a synthetic antagonist ERRα. 
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decreased the serum levels of the bone resorption marker C-terminal telopeptide 
fragments of the type I collagen (CTX-1) in WT mice; in contrast, this effect was 
completely abolished in the ERRα-/- mice (Figure 2.11a). Moreover, CTX-1 was reduced 
to a similar extent by both cholesterol ligand deletion in the zoledronate-treated mice (-
82%) and by receptor deletion in the ERRα-/- mice (-80%) (Figure 2.11a). In line with 
these results, microCT analysis of the proximal tibiae show that zoledronate significantly 
increased bone mass in WT mice but not in ERRα-/- mice (Figure 2.11b-c). Furthermore, 
bone histomorphometry analysis show that zoledronate significantly reduced osteoclast 
surface and osteoclast number in WT mice but not in ERRα-/- mice (Figure 2.11d). 
Complementarily, as a gain-of-cholesterol-function approach, we fed WT or ERRα-
/- mice with a high-cholesterol-diet (HCD) for 4 weeks and compared them to chow-diet 
fed control mice. ELISA analyses showed that HCD feeding significantly elevated serum 
CTX-1 levels by 107% in WT mice, once again, this effect was completely abolished in 
the ERR-/- mice (Figure 2.11e). In agreement, microCT analysis of the proximal tibiae 
show that HCD feeding significantly decreased bone mass in WT mice but not in ERRα-
/- mice (Figure 2.11f-g). Furthermore, bone histomorphometry analysis show that HCD 
feeding significantly increased osteoclast surface and osteoclast number in WT mice but 
not in ERRα-/- mice (Figure 2.11h). These in vivo studies indicate that the physiological 
function of cholesterol and the pharmacological actions of cholesterol-lowering drugs 
requires ERRα, further supporting the notion that cholesterol is a functional endogenous 
ERRa agonist. 
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Figure 2.11:  ERRα mediates cholesterol function in vivo. Osteoprotective 
effects of zoledronate was abolished in ERRα-/- mice. WT or ERRα-/- mice (6 week 
old male, n=4) were treated with a single i.v. injection of zoledronate at 0.54 mg/kg 
or PBS vehicle control and analyzed 4 weeks later. a, Serum levels of the bone 
resorption marker CTX-1. b-c, MicroCT analysis of tibiae. b, Trabecular bone 
volume/tissue volume ratio (BV/TV). c, Representative CT images of the entire 
proximal tibia (scale bar, 1mm). d, Bone histomorphometry analysis of osteoclast 
surface/bone surface (Oc.S/BS) (top) and osteoclast number/bone area (Oc.N/B.Ar) 
(bottom). e-h, Bone loss induced by high cholesterol diet (HCD) feeding was 
abolished in ERRα-/- mice. WT or ERRα-/- mice (7 week old female, n=4) were fed 
with a HCD or chow control diet for 4 weeks. e, Serum levels of the bone resorption 
marker CTX-1. f-g, MicroCT analysis of tibiae. f, Trabecular BV/TV. g, 
Representative CT images of the entire proximal tibia (scale bar, 1mm). h, Bone 
histomorphometry analysis of Oc.S/BS (top) and Oc.N/B.Ar (bottom). Statistical 
analyses were performed with Student's t-Test and are shown as mean ± standard 
deviation; **, p<0.01; ***, p<0.005; ****, p<0.001; n.s., non-significant (p>0.05). 
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2.8 Conclusion 
 
 In conclusion, our metabolomics strategy has successfully deorphanized ERRα 
by identifying cholesterol as an endogenous ERRα ligand. This discovery led to the 
elucidation of a key mechanistic link for how cholesterol and ERRα regulate 
osteoclastogenesis: cholesterol promotes osteoclastogenesis by activating its receptor 
ERRα; and ERRα stimulates osteoclastogenesis by responding to a rise in cellular 
cholesterol level. Moreover, our findings illuminate new mechanistic insights for how 
clinically used drugs such as statins and bisphosphonates actually act. Particularly, our 
results question the long-standing hypothesis that the inhibition of osteoclast activity by 
bisphosphonates is due solely to the blockade of protein prenylation. Interestingly, there 
is crosstalk between ERRα and ERα, including recognition of the estrogen response 
element (ERE) by ERRα. Thus, in ER negative (ER-) breast cancer, the presence of 
ERRα is a negative prognostic factor as it compensates for the loss of ERα in addition 
to triggering the expression of ERα-independent genes23. The function of cholesterol as 
an ERRα ligand may also provide mechanistic insight into clinical studies suggesting 
that statins can be used to treat or prevent ER- breast cancer24,25. The presence or 
absence of ERRα in ER- breast cancer may be a prognostic factor for the effectiveness 
of cholesterol-lowering treatments as anti-cancer therapeutics. Although it remains to be 
seen whether modulation of ERRα transactivation through therapeutic regulation of 
cholesterol is universally effective in the clinical setting, the deorphanization of ERRα 
using a widely applicable approach opens a new frontier in nuclear receptor biology.  
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2.9 Methods 
 
Lipid Isolation: 
To mouse brain or kidney tissue 2 mL chloroform, 1 mL water, and 1 mL methanol was 
added.  Tissue was then dounced to homogeneity.  Solvent was collected and mortar 
and pestle were washed with an additional 1 mL chloroform, .5 mL water, and .5 mL 
methanol.  Fractions were pooled and centrifuged for 10 minutes at 3220 g.  The 
chloroform layer was collected and dried under nitrogen.  Lipids were then redissolved 
in DMSO at 40ul/mg.   
Sterol Isolation: 
Sterols were prepared in the same manner as total lipids were except after drying under 
nitrogen sterols were redissolved in 1 mL toluene.  They were then fractionated from 
total lipids using solid phase extraction (BJ9050).  The column was equilibrated with 1 
mL hexanes, and then loaded with the lipid sample.  The column was then washed with 
hexanes (1 mL) and sterols were eluted with 30% isopropanol in hexanes (8 mL).  After 
elution the sample was dried under nitrogen and redissolved to 40uL/mg. 
A 4% solution (v/v) of sterol mix in buffer (20mM Tris, 200mM NaCl, pH 8.0) was 
made, and 20uL: of this lipid sample was injected on LC-MS (Agilent 6140) to check 
that sterols were dissolved.  In all cases cholesterol ion intensity was greater than 
200,000 counts.   
Recombinant Protein Expression 
The HIS-ERRα-LBD plasmid reported by Greshik et al26 was provided courtesy of Dino 
Moras.  HIS-ERRα-LBD was expressed in Rosetta 2 (DE3) cells.  Terrific broth was 
inoculated with a 1:50 dilution of starter culture.  Cells were grown to OD .4 at 37°C and 
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then moved to 18°C.  Once they reached OD .8 they were induced with .1mM IPTG and 
grown for 16 hours before harvesting. 
Purification of HIS-ERRα-LBD: 
HIS-ERRα-LBD was purified by nickel affinity chromatography and size exclusion 
chromatography.  
Global lipid pull down: 
Centrifuge columns (Pierce product #89868) were loaded with 10uL IMAC sepharose 6 
Fast Flow beads (GE).  Beads were washed with water (2 x 500uL) and the wash was 
eluted by centrifugation.  100uL .2M nickel sulfate was added to each column and the 
column was incubated for 30 minutes.  Nickel sulfate was then eluted and columns were 
washed with water (3 x 100uL) and protein buffer (20mM Tris, 200mM NaCl, pH 8.0) (3 
x 200uL).  200uL of 25uM or 50uM HIS-ERRα-LBD or protein buffer containing no 
protein was incubated with resin for 2 hours.  After incubation, protein was eluted and 
beads were washed with protein buffer containing 50mM imidazole (3 x 200uL).  100uL 
buffer containing 4% or 12% lipid mix by volume was added to each column and 
incubated for 30 minutes.  The lipid mixture was then eluted and columns were washed 
with protein buffer containing 50mM imidazole (3 x 100uL).  Protein-lipid conjugate was 
then eluted with protein buffer containing 250mM imidazole (3 x 100uL).  80uL were 
injected on LC-MS TOF in negative or positive mode.  This procedure was done in 
triplicate. 
LC Gradient: 
Solvent A: 95% Water, 5% Methanol 
Solvent B: 60% Isopropanol, 35% Methanol, 5% water 
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Positive mode solvent modifier: 5mM ammonium formate .1% formic acid 
Negative mode solvent modifier: .1% ammonium hydroxide.   
A gradient from 0-100% solvent B was run over 58  minutes on a C4 biobond 5µm, 50 x 
4.6 mm column.   
Data Analysis: 
After LC-MS TOF analysis, data from replicates was aligned using XCMS.  Data was 
filtered for ions with greater than 100,000 average counts in either the protein or resin 
samples.  Ions that were not present in the lipid sample alone were also removed.  To 
identify ions of interest, data was further filtered for a p value of less than .05 (1 tailed t-
test) and a fold change of greater than 2.   
Pull down for the targeted identification of sterols: 
The ERRα sterol pulldown was performed as the global lipid pulldown above except a 
sterol mixture was used in place of a lipid mixture.  4% (v/v) sterol mixture was used in 
20mM Tris, 200mM NaCl pH 8.0 buffer for the sterol pulldown.  After elution, aliquots 
were extracted into chloroform using a chloroform-methanol-water mixture (2:1:1) and 
dried down under nitrogen.  Then they were redissolved in 30uL water and 20uL was 
injected on LC-MS QQQ (Agilent 6140). 
MRM sterol analysis method: 
Our method to identify sterols was developed  from work by Shan et al. and Mcdonald 
et al27,28.  Sterols were analyzed on an Agilent 6140 LC-MS QQQ.  Solvent A was 85% 
methanol, 15% water, and 5mM ammonium acetate.  Solvent B was 100% methanol 
and 5mM ammonium acetate.  A phenomenex C18 100Å 250x2mm 3 micron column 
was used. 
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This method to identify sterols was developed from work by Shan et al. and Mcdonald et 
al27,28. 
 
MS/MS analysis: 
Gas Temp: 100°C 
Gas flow (l/min): 8 
Nebulizer (psi): 35 
Capillary (V) 4000 
 
Table 2.1 MRM sterol analysis global 
profiling gradient. 
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Diethylstilbestrol enrichment: 
The lipid mixture was spiked with 79uM diethylstilbestrol (DES), and the global lipid 
pulldown procedure above was repeated with this mixture.  After LC-MS TOF, 
diethylstilbestrol levels were analyzed in the extracted ion chromatogram. 
Diethylstilbestrol inhibition of cholesterol binding: 
The sterol mixture was spiked with 79uM DES and the pull down for the targeted 
identification of sterols was repeated as above using this mixture. 
Circular Dichroism: 
Solutions of 6.36uM HIS-ERRα-LBD in 20mM Tris, 200mM NaCl pH 8.0 2% ethanol 
(v/v) were incubated with 100uM small molecule for 5 minutes. Then circular dichroism 
Table 2.2:  MRM mass spectrometry method for the targeted identification of 
sterols. 
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was measured on JASCO J-710 spectrophotometer.  Four measurements were 
averaged. 
Tryptophan Fluorescence Quenching: 
Cholesterol was titrated into 350uL of .6uM HIS-ERRα-LBD.  The sample was excited at 
280nm and fluorescence emission was collected at 333nm with a cutoff filter at 325nm. 
Docking Simulations: 
Docking simulations were conducted with autodock vina (vina.scripps.edu) using the 
ERRα LBD crystal structure 2JPL in the protein data bank.  A cholesterol structure was 
generated in ChemBioDraw.  The simulation was centered at x coordinate -12, y 
coordinate -10, z coordinate 12.  Simulation box size was x=22, y=22, z=22.  The 
simulation was performed with a step size (exhaustiveness) of 1000. 
Fluorescence Polarization Experiments: 
25-NDB cholesterol and 6-NDB cholesterol were used at concentrations of 4.4uM and 
3.8uM respectively in 20mM Tris 200mM NaCl pH 8.0 5% ethanol (v/v).  HIS-ERRα-
LBD was added and samples were excited at 480nm and emission was measured at 
560nm for 25-NBD cholesterol and 550nm for 6-NBD cholesterol.   
ERRα AAA sterol pulldown: 
This lipid pulldown was performed as described above except sterols were dissolved in 
ethanol instead of DMSO. 
Luciferase, and osteoclast differentiation, and knockout mice assays: 
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Transfection and luciferase reporter assay were performed in CV-1 cells as described3. 
Bone marrow osteoclast differentiation assays and bone analyses (microCT, ELISA and 
histomorphometry) were performed as described3. ERRα knockout mice on a C57B6/J 
background was previously described3,4. Zoledronate was administered by a single 
intravenous injection at 0.54 mg/kg. High cholesterol diet (2% cholesterol, 0.5% 
NaCholate) and normal chow diet control were from Harlan Teklad. All statistical analyses 
were performed with Student's t-Test and presented as mean ± standard deviation (s.d.).  
The p values were designated as: *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001; n.s. 
non-significant (p>0.05). 
. 
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3.1 Introduction 
The complexity of the small proteome remains incompletely explored because 
genome annotation methods generally break down for small open reading frames 
(ORFs), generally with a length cutoff of 100 amino acids. Computational1 and ribosome 
profiling2 studies have suggested that thousands of these non-annotated mammalian 
sORFs are translated. However, since these studies did not directly detect the presence 
of any sORF-encoded polypeptides (SEPs), it remains unknown whether sORFs 
produce polypeptides that persist in cells at biologically relevant concentrations, or are 
rapidly degraded. Indeed, biochemical analysis of the translation of two sORFs 
identified in the yeast GCN4 gene by ribosome profiling revealed that only one 
expressed detectable polypeptide product3.  Moreover, recent evidence indicates that 
ribosome profiling can lead to widespread false positive identification of sORFs that 
encode polypeptides, and that mass spectrometry is the only surefire method to identify 
SEPs4.  
If SEPs do exist at physiologically relevant concentrations in cells, they may 
execute biological functions. Short open reading frames (sORFs) in the 5’-untranslated 
region (5’-UTR) of eukaryotic mRNAs (uORFs) are well studied5-7 and some have been 
shown to produce detectable polypeptides8,9. In addition to uORFs, other sORFs in 
bacteria10, viruses11, plants12,13, Saccharomyces cerevisiae14, Caenorhabditis elegans15, 
insects16,17, and humans18 have recently been discovered to produce polypeptides. 
Notably, the peptides encoded by the polycistronic tarsel-less (tal) gene in Drosophila, 
which are as short as 11 amino acids, regulate fly morphogenesis16,17.  
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While no general method for discovering SEPs exists, attempts have been made 
to systematically identify these molecules. In E. coli, for example, experiments in which 
predicted sORFs were epitope-tagged revealed 18 SEPs19.  In another example, a 
combination of computational and experimental approaches identified 299 potentially 
coding sORFs in S. cerevisiae, four of which were confirmed to produce protein and 22 
of which appeared to regulate growth14. In human cells, an unbiased proteomics 
approach identified a total of four SEPs (defined here as polypeptides that are 
synthesized on the ribosome at a length of less than 150 amino acids) between the 
K562 and HEK293 cell lines with a length distribution of 88-148 amino acids20. The 
discordance between the small number of SEPs detected in human cells20 and the large 
number of coding sORFs described by ribosome profiling2 and computational methods1 
leaves open the possibility that SEPs are not produced as predicted or are rapidly 
degraded and therefore not detectable.  
 To resolve this question we developed of a novel SEP discovery and validation 
strategy that combines peptidomics and massively parallel RNA sequencing (RNA-Seq) 
(Figure 3.1). This strategy uncovered 90 SEPs, 86 novel SEPs, the largest number of 
human SEPs ever reported, which demonstrates that SEPs are much more abundant 
that previously reported. In addition, characterization of the encoding sORFs revealed 
interesting non-canonical translation events that give rise to SEPs, including bicistronic 
expression and the use of non-AUG start codons. One SEP, derived from the DEDD2 
gene, localizes to mitochondria, which suggests that SEPs could generally have specific 
cellular localizations and functions. Together, these results highlight SEPs as an 
interesting class of polypeptides within the human proteome.  
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3.2 Discovering SEPs Encoded by Annotated Transcripts 
 We developed a novel strategy that combines peptidomics and massively parallel 
RNA sequencing (RNA-Seq) to discover human SEPs (Figure 3.1). Peptidomics 
augments the traditional liquid chromatography-tandem mass spectrometry (LC-
MS/MS) proteomics workflow to preserve and enrich small polypeptides21. In this 
context, the use of peptidomics increases the total number of SEPs detected, including 
a greater number of shorter SEPs. We isolated peptides from K562 cells, a human 
leukemia cell line, because we could use the previously reported SEPs in this cell line 
as positive controls20. Endogenous K562 polypeptides were isolated using our standard 
peptidomics workflow21 with great care being taken to reduce proteolysis. Proteolysis is 
detrimental because the processing of cellular proteins greatly increases the complexity 
of the peptidome, which deteriorates the signal-to-noise ratio during the subsequent 
analysis22. After isolation, the K562 polypeptides were digested with trypsin and 
analyzed by LC-MS/MS (Figure 3.2). Based on previous results from our lab23 and  
 
 
Figure 3.1 Workflow for identifying short ORF encoded peptides (SEPs).  
63 
 
others24 the optimal size for detection by LC-MS/MS is approximately 10-20 amino 
acids, indicating that SEPs detection would greatly benefit from trypsin proteolysis.  
To identify SEPs it was necessary to use a modified protocol for LC-MS/MS data 
analysis. Standard proteomics and peptidomics approaches identify peptides by 
matching experimentally observed spectra to databases of predicted spectra based on 
annotated genes, which would not include SEPs. We tore created a custom database 
containing all polypeptides that could possibly be translated from the human 
transcriptome (RefSeq). Using Sequest, an analysis program used to identify peptides 
from MS/MS spectra25,26, we compared >200,000 MS/MS peptide spectra to this 
RefSeq-derived polypeptide database. This resulted in 6548 unique peptide 
identifications. We arrived at a tentative list of SEPs by keeping only those tryptic 
peptides that differed by at least two amino acids from every annotated protein to 
minimize the possibility of false positives arising from polymorphisms in annotated 
genes.  
 Due to the small size of SEPs, it is unlikely that an unbiased peptidomics 
experiment will detect more than one tryptic fragment of a given SEP, though eleven 
SEPs did have two or more fragments. This contrasts with standard proteomics studies, 
which, on account of the numerous tryptic fragments generated from full size 
polypeptides, will typically uncover two or more peptides to support the presence of a 
protein. Realizing that we would likely not be able to rely on the confidence contributed 
by the inherent redundancy of multiple-peptide protein identifications for SEP discovery, 
we submitted the candidate peptide spectrum matches (PSMs) to a rigorous evaluation 
procedure to ensure the highest confidence for each SEP.  
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 First, we discarded any PSM with an Sf score of less than 0.75 (the threshold for 
a typical proteomics experiment is Sf < 0.427). This eliminated over 95% of the 
candidate set. We then visually examined each remaining MS/MS spectrum to ensure 
that it met a stringent set of criteria (Figure 3.2). In particular, we required that there be 
a sequence tag of five consecutive b- or y-ions, a precursor mass error of <5 ppm, and 
sufficient sequence coverage to unambiguously differentiate each peptide from every 
annotated protein sequence. This step reduced the remaining peptide pool by 
approximately 75%, for a total of 39 putative SEPs. Our PSM evaluation procedure 
therefore selected the most confident ~1% of the peptide identifications in our original 
candidate set. As a check on the effectiveness of this procedure, we compared the 
experimentally-collected MS/MS spectra of several identified peptides to that of identical 
synthetic peptides (Figure 3.2).  
 
 
Figure 3.2: SEP MS/MS Criteria and Spectra.  (A) Criteria for identifying SEPs.  
(B)  We validated a select number of detected peptides by synthesizing them and 
comparing them to the endogenous spectra.  (Top) Diagnostic spectra.  (Bottom) 
Endogenous spectra.  
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Lastly, to further reduce the probability of false positives, we comprehensively 
assembled and cataloged the K562 transcriptome using RNA-Seq and crosschecked 
the assembled RNA-Seq transcripts against our candidate sORF list. In this manner we 
 
Figure 3.3: Overview of SEPs.  (A)  RNA maps illustrate the categories of 
sORFs that are translated into SEPs including 5’ UTR, CDS, 3’ UTR, ncRNA, 
and antisense sORFs.  (B)  Incidence of each category of SEPs within the 
RefSeq mRNAs.  (C) Using protein databases derived from K562 RNA-Seq 
data revealed an additional 54 SEPs for a total of 90 human SEPs, 86 of which 
are previously uncharacterized.  (D)  Probable sORF initation codon usage.  
RNA maps are not to scale.  
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confirmed that at least 37 of the 39 implicated sORFs are present in this cell line and 
that no other sequence in the assembled K562 RNA-Seq transcripts could produce the 
detected peptides (Figure 3.3). This eliminated the possibility that the detected SEPs 
arose from point mutations in annotated genes, longer unannotated ORFs containing 
identical tryptic peptides, or post-transcriptional modification or editing of RNAs. 
Importantly, a similar analysis without trypsin failed to identify any SEPs demonstrating 
the importance of trypsin in generating an ideal sample for LC-MS/MS. 
The 37 SEPs discovered through analysis of RefSeq transcripts fall into five 
major categories: (i) those located in the 5’-UTR, (ii) those located in the 3’-UTR, (iii) 
those located (frameshifted) inside the main coding sequence (CDS),  (iv) those located 
on non-coding RNAs (ncRNAs), and (v) those located on antisense transcripts (Figure 
3.3 A and B). The locations of these sORFs mirror the distribution obtained from 
ribosome profiling2, indicating that our peptidomics coverage achieves the necessary 
breadth and depth to reveal global properties of sORFs (Figure. 3.3 B). Many of these 
SEPs appear to be derived from polycistronic mRNAs, which is interesting because this 
phenomenon has historically been thought to be rare in eukaryotes. However, our 
findings here are again consistent with those of ribosome profiling studies2.  
3.3 SEPs are Derived from Unannotated Transcripts 
Some SEPs may have been overlooked (false negatives) in our analysis of 
RefSeq transcripts due to the presence of RNAs in K562 cells that are not annotated in 
the RefSeq database. To account for such RNAs we also analyzed the LC-MS/MS 
peptidomics data using a second custom database derived from K562 RNA-Seq data. 
Furthermore, recognizing that recent ribosome profiling studies identified a number of 
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sORFs within the pool of long intergenic non-coding RNAs (lincRNAs) in mouse 2, we 
generated an extensive catalog of K562 lincRNAs by applying a previously described 
lincRNA-calling pipeline28 to our RNA-Seq data and searched the corresponding protein 
database against our data sets. We applied the same stringent criteria for scoring and 
assessing peptide-spectral matches, and eliminating peptides with fewer than two 
differences from annotated proteins; we also eliminated any peptides of fewer than 8 
amino acids in order to further reduce false positives. These analyses yielded an 
additional 54 SEPs.  
 Combining the RefSeq and RNA-Seq results, we discovered 90 unannotated 
SEPs, four of which were previously reported and thus served as positive controls20, 
and 86 of which are novel (Figure 3.3 C). The average length of each peptide identified 
using this approach was 13-14 amino acids and 90% of the peptides were longer than 
18 amino acids, which supports the use of trypsin to generate an ideal LC-MS/MS 
sample for SEP discovery. This is the largest number of SEPs ever reported in a single 
study and increases the total number of known human SEPs18,20 by ~18-fold, 
demonstrating the superior coverage afforded by our approach. Interestingly, analysis of 
the evolutionary conservation of the SEPs across 29 mammalian species suggested 
that SEPs are more conserved than introns, but not as conserved as known coding 
genes29 (Figure. 3.4). 
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3.4 SEP Translation is Initiated at Non-AUG Codons  
 Because we performed mass spectrometry on trypsin-digested samples, we do 
not obtain full protein-level SEP sequence coverage, and in particular do not directly 
observe the N terminus. We therefore assigned the likely start codon for each SEP in 
order to determine their lengths. When present, an upstream in-frame AUG was 
assumed to be the initiation codon. If no upstream AUG was present, the initiation 
codon was assigned to an in-frame near-cognate non-AUG codon embedded within a 
Kozak-consensus sequence 30. In a few cases, neither of these conditions was met, so 
 
Figure 3.4:  Conservation of sORFs.  sORFs are conserved more than introns, but 
less than known coding genes.  Higher omega indicates less conservation. 
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the codon immediately following an upstream stop codon was used to determine 
maximal SEP length.  
Using this approach, we determined the SEPs to be 18-149 amino acids long, 
with the majority (~ 80%) being <100 amino acids (Figure 3.3 C). If we take a more 
conservative approach by using an AUG-to-stop or upstream-stop-to-stop, we obtain 
similar SEP length distribution and retain our smallest SEPs. As the shortest human 
SEP previously identified by mass spectrometry was 88 amino acids long20, it is clear 
that our approach provides superior coverage of small SEPs. This is significant because 
many previously characterized, functional SEPs in other species are under 50 amino 
acids10,16-18.  
Another interesting feature of our results is the preponderance of non-canonical 
translation start sites: 57% of the detected SEPs do not initiate at AUG codons (Figure 
3.3 D). This finding is consistent with the results of ribosome profiling experiments in 
mouse, which indicate that, globally, most ORFs contain non-AUG start sites2. Below 
we obtain data demonstrating that these non-AUG sites are the actual initiation codons 
of the sORFs. 
3.5 Supporting SEP length assignments 
 
We used two approaches to gain additional insight into the lengths of our SEPs. 
First, rather than relying solely on a molecular weight cutoff filter we decided to use 
polyacrylamide gel electrophoresis (PAGE) to better separate the K562 lysate into 
different molecular weight fractions. PAGE can be used as a molecular weight 
fractionation method prior to proteomics and this approach has successfully been used 
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to study proteolysis31. With SEPs, PAGE would provide a tighter molecular weight 
range, which would support the assigned lengths of the SEPs. Indeed, analysis of the 
~10-15 kDa portion of the K562 found SEPs that we had identified as being 90-120 
amino acids in length, supporting that these SEPs are intact in these cells which would 
lead them to migrate at ~10-15 kDa. Importantly, for some of these SEPs we also find 
additional peptides from the SEP to provide even greater confidence in the SEP 
assignments.  
 We still needed to demonstrate that full-length SEPs are present in K562 lysates 
and therefore we elected to perform an isotope-dilution mass spectrometry (IDMS) 
experiment with chemically synthesized full-length SEPs. Specifically, we prepared two 
SEPs, MLHSRKRELRQVLITNKNQVLITNKQVRLTLLLTLG and 
MLRCFFPKMCFSTTIGGMNQRGKRK, with a deuterated leucine (d10-Leu, amino acid 
that is bold, red and in italics). These two peptides were then added to K562 lysate and 
the sample was analyzed by LC-MS. These peptides co-eluted with peptides from the 
sample with the correct mass for the natural SEPs (Figure 3.5). Due to the high charge 
state of the peptides (+5 ions) the tandem MS (CID) was not informative, which led us to 
use additional methods for confirmation including IDMS of trypsin fragments and cellular 
imaging experiments. Our current instrumentation configuration is not designed to easily 
measure full-length SEPs directly from lysates, however, other mass spectrometry 
methods including top-down proteomics32 and high-resolution mass spectrometry 
approaches for peptide detection33, should enable the discovery and/or validation of full-
length SEPs in the future. 
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3.6 Cellular Concentrations of SEPs 
 We wished to explore the biological properties of SEPs. First, we examined the 
cellular concentrations (K562 cells) of three selected SEPs (ASNSD1-SEP, PHF19-SEP 
and H2AFx-SEP) using isotope dilution mass spectrometry34. (We refer to SEPs by 
appending “-SEP” to the name of the annotated CDS nearest the sORF; the sORF is 
given the same name but italicized.) These SEPs were found at concentrations between 
10 and 2000 copies per cell. Thus, based on previous estimates of protein copy 
numbers, SEPs are found at concentrations well within the range of typical cellular 
 
 
Figure 3.5:  Isotope dilution mass spectrometry (IDMS) of full length deuterated 
and endogenous SEPs.  Coelution demonstrates correct assignment of the full 
length SEP from the detected peptide. (A) Coelution of 
MLRYCFFPKMCFSTTIGGMNQRGKRK with a synthetic peptide and coelution of 
MLHSRKRKELRQVLITNKNQVLITNKNQVRLTLLLTLG (B) demonstrate correct 
identification of the full length SEP.  (C)  Predicted and observed precursor ion 
masses of the synthetic and endogenous peptides.  The CID of these peptides was 
uninterpretable due to the length of these peptides, but coelution indicates correct 
identification.    
 
72 
 
proteins35-37. We further note that the MS/MS spectra from the synthetic standards used 
in these experiments were nearly identical to those produced from the endogenous 
peptide and eluted at the same retention time as same, thus confirming these 
identifications (Figure 3.6) 
 
3.7 Heterologous Expression of SEPs 
We tested whether the implicated RNA transcripts and sORFs were competent to 
produce SEPs. Constructs were designed to produce full-length mRNAs, including 5’ 
and 3’ UTRs, that matched those in the RefSeq database38. We selected sORFs in the 
5’-UTR, the 3’-UTR, or frameshifted within the CDS, and encoded a FLAG epitope tag 
at the 3’-end of each sORF (so that initiation is unperturbed). The uORFs ASNSD1-
SEP, PHF19-SEP, DNLZ-SEP, EIF5-SEP, FRAT2-SEP, YTHDF3-SEP, CCNA2-SEP, 
 
Figure 3.6: SEP quantification.  We synthesized deuterated variants of tryptic SEPs.  
(A)  Upon preparation of the K562 peptidome, deuterated SEPs were added 
exogenously, and the entire mixture was subjected to LC-MS.  SEPs were then 
quantified by comparing the peak areas of the deuterated and endogenous peptide.  As 
the concentration of the deuterated SEP is known, this allowed for the absolute 
quantification of the SEP.  Coelution of the endogenous and deuterated peptides 
confrims the identification of the endogenous SEP peptide.  (B)  Matching MS/MS 
spectra of the heavy and light peptide confirm sequence assignment.  10 Da shifts in 
some of the MS/MS peaks are due to the presence of the deuterated leucine. 
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DRAP1-SEP, TRIP6-SEP, and C7ORF47-SEP all produced cytoplasmically localized 
polypeptides, as detected by anti-FLAG immunofluorescence in transfected HEK293T 
cells (Figure 3.7 and Figure 3.8). Most importantly, the fact that FRAT2-SEP, YTHDF3-
SEP, CCNA2-SEP, DRAP1-SEP, TRIP6-SEP, C7ORF47-SEP, which do not have any 
upstream in frame AUG codons, produced SEPs verifies that sORFs with non-AUG 
start codons are translated (Figure 3.7 and Figure 3.8).  
 
 
Figure 3.7 Expression of SEPs from their endogenous RNAs.  HEK293T cells 
were transiently transfected with a cDNA construct containing the full length RefSeq 
mRNA sequence to which SEPs were assigned.  The sORF was flagged at the C-
terminus.  Expression was examined by immunofluorescence (green) and nuclei were 
stained with Hoescht or Dapi (blue).  SEP expression from sORFs originating in the 
5’UTR could be observed.  sORF originating in the CDS or 3’UTR did not appear to 
result in SEP expression.  However, RNA-Seq data indicated that at least some of 
these had transcript variants where the sORF was the first AUG on the transcript.  
74 
 
 
 By contrast, the DEDD2-SEP sORF was not translated from the full-length 
RefSeq construct. DEDD2-SEP is frameshifted deep within the main CDS of the 
DEDD2 transcript, so according to the scanning model of translation39 it is not expected 
that this downstream sORF would be translated (Figure 3.7). One possible explanation 
for our observation of the DEDD2-SEP is that it is translated from a splice variant of the 
DEDD2 RNA that is present in K562 cells, but is not in RefSeq. In support of this 
 
Figure 3.8: Validation of SEP expression.  An additional pool 
of SEPs were expressed from their Refseq transcripts in order 
to further validate SEP expression. 
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hypothesis, we identified a truncated DEDD2 mRNA in the RNA-seq data wherein the 
first start codon is that of the DEDD2-SEP sORF (Figure 3.9). The 3’-UTR-embedded 
H2AFx-SEP was similarly not translated from the full-length mRNA construct; however, 
we were not able to clearly identify a truncated version of the H2AFx transcript in the 
K562 RNA-seq data. It is possible that a truncated H2AFx mRNA variant is present in 
K562 cells but is not detectable or not resolvable from the full-length H2AFx transcript.  
                
3.8 SEPs Exhibit Subcellular Localization 
 We subcloned expression constructs for FLAG-tagged DEDD2-SEP and H2AFx-
SEP to determine whether these SEPs are stable. The H2AFx-SEP sORF produced a 
cytoplasmic polypeptide in HEK293T cells (Figure 3.10).  
 
Figure 3.9:  DEDD2 has truncated transcript variants.  RNA-
Seq data indicates there are multiple transcript variants of 
DEDD2.  In some of these variants the 5’ end of the transcript is 
truncated, and the transcript lacks the DEDD2 CDS start codon.  
In these transcripts the sORF initiation codon is the first AUG on 
the transcript. 
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Interestingly, DEDD2-SEP localizes to mitochondria in HEK293T, mouse embryonic 
fibroblast (MEF), and COS7 cells, as demonstrated by co-localization with the 
mitochondrial marker MitoTracker Red (Figure 3.11). The N-terminus of DEDD2-SEP is 
predicted to contain a mitochondrial import signal40. Sequence-dependent trafficking 
and subcellular localization of SEPs could therefore be general phenomena related to 
their biological activities.  
 
 
Figure 3.10:  H2AFx SEP is cytoplasmic.  Expression of the H2AFx flag tagged 
sORF demonstrated H2AFx-SEP was a cytoplasmic polypeptide in HEK293T cells. 
 
Figure 3.11: DEDD2-SEP localizes to the mitochondria.  DEDD2-SEP-sORF was 
expressed in HEK293T, MEF, and COS7 cells in order to examine its localization (green).  
Costaining with MitoTracker (red) indicated DEDD2-SEP localized to the mitochondria. 
77 
 
3.9 Non-AUG Start Codons Enable Bicistronic Expression 
 Since such a large proportion of SEPs putatively initiate at non-AUG sites, we 
wanted to rigorously identify the alternate start codon of one these sORFs. C-terminally 
FLAG-tagged FRAT2-SEP was expressed from the full-length mRNA construct in 
HEK293T cells and immunoprecipitated; mass spectrometry of the purified protein 
(Figure 3.11) was consistent with initiation at an ACG triplet embedded within a Kozak 
consensus sequence30 (Figure 3.12).  
 
 Mutating the ACG to an ATG resulted in increased FRAT2-SEP translation while 
deletion of this ACG abolished FRAT2-SEP production, as assessed by Western 
blotting, thus confirming our assignment (Figure 3.13). In addition, mutation of the 
Kozak consensus sequence to less favorable residues led to markedly lower FRAT2-
SEP expression, which demonstrates the importance of the Kozak sequence at non-
AUG initiation sites.  
 
 
 
Figure 3.12: FRAT2 ACG misprimes for methionine.  Immunoprecipitation of 
FRAT2 SEP followed by MALDI indicated FRAT2 has initiates with a methionine 
despite an ACG initiation codon. 
78 
 
 
 The scanning model of translation provided an explanation as to why the DEDD2 
mRNA is not bi-cistronic; we hypothesized that upstream alternate start codons could 
provide a mechanism to promote polycistronic gene expression via leaky scanning. To 
test whether FRAT2 mRNA is bi-cistronic, we prepared a FRAT2 construct where the 
SEP and the downstream CDS were tagged with different epitopes (Figure 3.13), 
permitting their simultaneous detection by immunoblotting with two antibodies. We 
found that the FRAT2 RNA is bi-cistronic, as FRAT2 and FRAT2-SEP are both 
expressed (Figure 3.13). Remarkably, mutation of the ACG start codon of the FRAT2-
 
Figure 3.13  FRAT2 mRNA is bicistronic.  (A)  The FRAT2 cDNA expression 
construct, with a Flag epitope tag appended at the C terminus of the FRAT2-
SEP sORF was subjected to site-directed mutagenesis to probe the identity of 
the sORF start codon by expression in HEK293T cells followed by western 
blotting.  Below the immunoblot, the sORF Kozak and start codon sequences of 
the expressed construct are shown, with the start codon shown in uppercase 
and sites of mutation highlighted in red.  Conversion of the putative ACG start 
codon to an ATG resulted in higher expression (lane 3).  In addition, 
perturbation of the kozak sequence (lane 4-7) revealed the importance of 
context when using non-AUG codons, as substitution of less favorable residues 
resulted in lower FRAT2-SEP expression.  Equal loading was demonstrated 
with actin specific immunoblotting.  (B)  Epitope tagging of the sORF and CDS 
of the FRAT2 mRNA demonstrates that the FRAT2 mRNA is bicistronic.  The 
FRAT2 CDS was c-myc tagged, and the FRAT2-SEP was Flag tagged.  
Conversion of the FRAT2-SEP initiation codon from ACG to ATG ablates 
expression of the downstream FRAT2 CDS, indicating the importance of 
alternate start codons for polycistronic expression.  RNA maps are not to scale. 
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SEP to an ATG increases FRAT2-SEP expression, but also completely eliminates the 
expression of FRAT2 protein, revealing that the translation of the downstream cistron 
absolutely requires leaky upstream initiation. Therefore, this experiment indicated that 
an upstream non-AUG initiation codon is necessary for efficient polycistronic gene 
expression. 
While we attribute FRAT2-SEP translation and bi-cistronic expression to 
alternate start codon use, we note that another interesting mechanistic possibility for 
FRAT2-SEP translation is partial (or incomplete) RNA editing, which could modify the 
ACG to AUG post-transcriptionally. The role of RNA editing in generating sORF start 
codons at the RNA level could be studied in the future via genetic knockout of the 
enzymes responsible for this activity41. 
3.10 A Small Subset of lincRNAs encode SEPs 
Another intriguing feature of these experiments was the discovery of SEPs 
encoded by lincRNAs. lincRNAs have emerged as an important class of regulatory 
molecules with intrinsic biological functions (e.g., hotair, xist)42,43. Ribosome profiling 
experiments in mouse cells indicate the presence of translated sORFs on nearly half of 
the lincRNAs analyzed2, which is much higher than expected42,44,45. By contrast, our 
peptidomics analysis identified 8 SEP-encoding lincRNAs, which represents just 0.4% 
of the1866 lincRNAs detected in our RNA-seq analysis of K562.  
This disparity may result from a number of factors, including false positive 
identifications by ribosome profiling techniques 3,4.  Indeed, many of these IDs were 
later found to be erroneous by more thorough re-analysis of ribosome profiling data4. 
Additionally, ribosome profiling may identify rare translational events that do not 
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generate enough protein to be detected by LC-MS/MS, since mass spectrometry is 
biased towards the detection of more abundant peptides46. It is also possible that some 
of the sORFs identified by ribosome profiling may produce polypeptides that are rapidly 
degraded and therefore would be undetectable using any analytical approach. Future 
work coupling ribosome profiling with mass spectrometry should help resolve these 
questions and provide a better understanding of the factors governing SEP expression.  
3.11 Conclusion 
In contrast to previous attempts to use mass spectrometry to discover 
unannotated human coding sequences, we successfully access the pool of SEPs that 
are under 50 amino acids in length. This is unprecedented for a global discovery 
technique and is a crucial step towards understanding the biology of these molecules, 
for many of the known SEPs16-18 are below this size threshold. Moreover, the unbiased 
discovery of SEPs also provided insights into protein translation through the 
characterization of non-AUG codons and validation of mammalian polycistronic gene 
expression. Taken together, these findings provide the strongest evidence to date that 
coding sORFs constitute a significant human gene class. Moreover, due to the bias of 
mass spectrometry for more abundant species46, which limits the scope of our 
technique to the most highly expressed SEPs, and our conservative identification 
criteria it is probable that there are many more as-yet-undiscovered human SEPs. Thus, 
we believe we have only begun to explore the breadth and diversity of this new family of 
polypeptides. 
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3.12 Methods 
Cloning and mutagenesis: 
DNA constructs were prepared by standard ligation, Quikchange, or inverse PCR 
techniques. Human cDNA clones were obtained from Open Biosystems and subcloned 
into pcDNA3, which uses a CMV promoter. Gene synthesis was performed by DNA2.0. 
Plasmid sequences are publicly available upon request. We note that the YTHDF3-SEP 
construct consisted of the 5’-UTR putatively encoding the SEP only, obtained via gene 
synthesis because a full-length cDNA construct with an intact 5’-UTR was not 
commercially available. 
Cell culture:  
Cells were grown at 37ºC under an atmosphere of 5% CO2. HEK293T, HeLa, COS7 
and MEF cells were grown in high-glucose DMEM supplemented with L-glutamine, 10% 
fetal bovine serum, penicillin and streptomycin. K562 cells were maintained at a density 
of 1-10 x 105 cells/mL in RPMI1640 media with 10% fetal bovine serum, penicillin and 
streptomycin. 
Isolation and processing of polypeptides:  
Aliquots of 3 x 107 growing K562 cells were placed in 1.5 ml Protein LoBind Tubes 
(Eppendorf), washed three times with PBS, pelleted and stored at -80 °C. Boiling water 
(500 µl) was added directly to the frozen cell pellets and the samples were then boiled 
for 20 minutes to eliminate proteolytic activity 21,23. After cooling to room temperature, 
samples were sonicated on ice for 20 bursts at output level 4 with a 40% duty cycle 
(Branson Sonifier 250; Ultrasonic Convertor). The cell lysate was then brought to 0.25% 
acetic acid by volume and centrifuged at 20,000 x g for 20 minutes at 4°C. The 
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supernatant was sent through a 30 kD or 10 kD molecular weight cut-off (MWCO) filter 
(Modified PES Centrifugal Filter, VWR). The mix of small proteins and peptides in the 
flow-through was evaluated for protein content by BSA assay and then evaporated to 
dryness at low temperature in a SpeedVac. Pellets were re-suspended in 50 µl of 25mM 
TCEP in 50mM NH4HCO3 (pH=8) and incubated at 37 °C for 1 hour. The reaction was 
cooled to room temperature before 50 µl of a 50 mM iodoacetamide solution in 50 mM 
NH4HCO3. This solution was incubated in the dark for 1 hour. Samples were then 
dissolved in a 50 mM NH4HCO3 solution of 20 µg/µl trypsin (Promega) to a final protein 
to enzyme mass ratio of 50:1. This reaction was incubated at 37 °C for 16 hours, cooled 
to room temperature and then quenched by adding neat formic acid to 5% by volume. 
The digested peptide mix was then bound to a C18 Sep Pak cartridge (HLB, 1cm3; 
30mg, Oasis), washed thoroughly with water and eluted with 1:1 acetonitrile/water. The 
eluate was evaporated to dryness at low temperature on a SpeedVac. 
Offline electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) 
fractionation of polypeptide fraction. 
 To simplify the sample and thereby improve detection sensitivity in the subsequent LC-
MS/MS analysis, we separated the processed peptide mix by ERLIC47,48. ERLIC was 
performed using a PolyWax LP column (200 x 2.1 mm, 5µm, 300Å; PolyLC Inc.) 
connected to an Agilent Technologies 1200 Series HPLC equipped with a degasser and 
automatic fraction collector. All runs were performed at a flow rate of 0.3 ml/min and 
ultraviolet absorption was measured at a wavelength of 210 nm. Forty (30 kD sample) 
or 25 (10 kD sample) fractions were collected over a 70 minute gradient beginning with 
0.1% acetic acid in 90% acetonitrile (aq.) and ending with 0.1% formic acid in 30% 
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acetonitrile (aq.). The fractions were then evaporated to dryness on a SpeedVac and 
dissolved in 15 µl 0.1% formic acid (aq.) in preparation for LC-MS/MS analysis. 
LC-MS/MS analysis. Samples were injected onto a NanoAcquity HPLC system 
(Waters) equipped with a 5 cm x 100 µm capillary trapping column (New Objective) 
packed with 5 um C18 AQUA beads (Waters) and a PicoFrit SELF/P analytical column 
(15 µm tip, 25 cm length, New Objective) packed with 3 µm C18 AQUA beads (Waters) 
and separated over a 90 minute gradient at 200 nl/min. This HPLC system was online 
with an LTQ Orbitrap Velos (Thermo Scientific) instrument, which collected full MS 
(dynamic exclusion) and tandem MS (Top 20) data over 375-1600 m/z with 60,000 
resolving power. 
Data processing: 
The acquired MS/MS spectra were analyzed with the SEQUEST algorithm using a 
database derived from 6-frame (forward and reverse) translation of RefSeq (National 
Center for Biotechnology Information) mRNA transcripts or 3-frame (forward only) 
translation of a transcriptome assembly generated by Cufflinks49 using RNA-Seq data 
from the K562 cell line (data acquisition described below). The search was performed 
with the following parameters: variable modifications, oxidation (Met), N-acetylation; 
semitryptic requirement; maximum missed cleavages: 2; precursor mass tolerance: 20 
ppm; and fragment mass tolerance: 0.7 Da. Search results were filtered such that the 
estimated false discovery rate of the remaining results was 1%. The Sf score is the final 
score for protein identification by the Proteomics Browser software based on a 
combination of the preliminary score, the cross-correlation and the differential between 
the scores for the highest scoring protein and second highest scoring protein27. 
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Identified peptides were searched against the Uniprot human protein database 
using a string-searching algorithm. Peptides found to be identical to fragments of 
annotated proteins were eliminated from the SEP candidate pool. The remaining 
peptides were searched against non-redundant protein sequences using the Basic 
Local Alignment Search Tool (BLAST). Any peptides found to be less than two amino 
acids different from the nearest protein match (i.e., identical or different by one amino 
acid) were discarded. 
The spectra of the remaining peptides were subjected to a rigorous manual 
validation procedure: spectra were rejected if they had a precursor mass error of >5 
ppm, if they lacked a sequence tag of 5 consecutive b- or y-ions, if they had more than 
one missed cleavage, or if they lacked sufficient sequence coverage to differentiate 
from the nearest annotated protein. Finally, peptides under 8 amino acids in length were 
discarded in order to further minimize false positive identifications. 
RNA-Seq library preparation, alignment, and transcriptome assembly: 
Two types of cDNA libraries were generated from K-562 RNA (Ambion). In the first 
experiment, we used 50 nanograms of polyA+ RNA to create standard, non-strand-
specific cDNA libraries with paired-end adaptors as previously described 50 and 
sequenced it on one lane of an Illumina Genome Analyzer IIa machine. In the second 
experiment, we used eight different amounts of total RNA (30 ng, 100 ng, 250 ng, 500 
ng, 1000ng, 3000 ng, and 10,000 ng) to create cDNA libraries with paired-end, indexed 
adaptors following the instructions for the Illumina TruSeq RNA sample prep kit, except 
that we used SuperScript III instead of SuperScript II and optimized PCR cycle number. 
These libraries were sequenced on a single lane of a HiSeq2000 machine. RNA-Seq 
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reads were aligned to the human genome (Hg19 assembly) using TopHat [version 
V1.1.4;51] and transcriptome assembly was performed using Cufflinks [version 
V1.0.0;49]. lincRNAs were called based on a lincRNA-calling pipeline as previously 
described28. The transcriptome data is deposited on GEO (GSE34740).  
Peptide synthesis, purification and concentration determination: 
Automated (PS3 Protein Technology, Inc.) solid-phase peptide synthesis was carried 
out using Fmoc amino acids. Crude peptides were HPLC (Shimadzu)-purified using a 
C18 column (150 mm × 20 mm, 10 µm particle size, Higgins Analytical). The mobile 
phase was adjusted for each peptide; buffer A was 99% H2O, 1% acetonitrile, and 0.1% 
TFA; buffer B was 90% acetonitrile, 10% H2O, and 0.07% TFA). Pure fractions were 
identified by MALDI-MS analysis, combined, and lyophilized. Peptide concentrations 
were determined by amino acid analysis (AlBio Tech). 
Absolute quantification of SEPs: 
Isotope dilution mass spectrometry (IDMS) 34 was used to determine the concentration 
of SEPs in K562 cells. All samples for this experiment were prepared by adding known 
amounts of heavy isotope-labeled peptides corresponding the detected fragment of the 
SEP of interest to a K562 cell pellet (107 cells) just before isolation of the polypeptides 
from these cells. The preparation of these samples was identical to that described 
above except that no ERLIC separation was done. The first step of the quantification 
procedure was to prepare a set of samples where each sample contained a different but 
known amount (1 fmol, 10 fmol, 50 fmol, 100 fmol, 500 fmol, 1 pmol or 10 pmol) of the 
heavy-labeled counterpart peptide. These samples were then analyzed by a selected 
ion monitoring (SIM) method on the previously described LC-MS/MS system and the 
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resulting data was analyzed using Xcaliber 2.0 (Thermo Scientific). The areas of the 
peaks corresponding to the endogenous and isotope-labeled peptides were compared 
to determine the approximate concentration of the SEP and a standard curve was 
generated to verify that the quantity of the SEP fragment was within the linear range of 
the mass spectrometer. A second set of samples that each contained an amount of 
isotope-labeled peptide that was within the linear range of the instrument and within an 
order of magnitude of the amount of the corresponding endogenous peptide in the cells 
was then prepared (N=4) and analyzed as described. The results of this experiment 
were used to determine the absolute cellular concentration of the selected SEPs. 
Imaging SEPs by immunofluorescence: 
HeLa, COS7, and MEF cells were grown to 80% confluency on glass coverslips in 48-
well plates; HEK293T cells were grown to 50-75% confluency on fibronectin (Millipore)-
coated glass coverslips in 48-well plates. Cells were transfected in Opti-MEM 
(Invitrogen) with 250 ng plasmid DNA using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s instructions. 24 hours after transfection, cells were fixed with 4% 
formalin in phosphate buffered saline (PBS) for 10 minutes at room temperature, and 
then permeabilized with methanol at -20ºC for 10 minutes. Fixed cells were blocked with 
blocking buffer (3% BSA in PBS with 0.5% Tween-20), then incubated overnight at 4ºC 
with anti-FLAG M2 antibody (Sigma) diluted 1:1000 in blocking buffer. After washing 3x 
with PBS, cells were then stained for one hour at room temperature with goat anti-
mouse AlexaFluor 488 conjugate (Invitrogen) diluted 1:1000 in blocking buffer. Cells 
were washed 3x with PBS, post-fixed with 4% formalin for 10 minutes at room 
temperature, then counterstained with a final concentration of 270 ng/mL Hoescht 
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33258 (Invitrogen) in PBS for 15 minutes at room temperature. Cells were then imaged 
in PBS in glass-bottom imaging dishes (Matek Corp.). For mitochondrial co-localization 
analysis, transfected cells were treated with MitoTracker Red CMXRos (Invitrogen) at a 
final concentration of 100 nM in PBS at 37ºC for 15 minutes, washed once with PBS, 
then fixed with formalin and methanol and immunostained as described above. 
Images were acquired in the Harvard Center for Biological Imaging on a Zeiss 
LSM 510 inverted confocal microscope with the following lasers: 405 Diode, 488 
(458,477,514) Argon, 543 HeNe and 633 HeNe. Image acquisition was with either AIM 
or Zen software. Images were acquired with a 60x oil immersion objective. 
Determination of the FRAT2-SEP start codon by immunoprecipitation and MALDI-MS: 
COS7 and HEK293T cells were grown in 10-cm dishes to 75% confluency, then 
transfected with 10 µg plasmid DNA using Lipofectamine 2000 according to the 
manufacturer’s instructions. 24 hours after transfection, cells were harvested by 
scraping and washed 3x with PBS. Cells were lysed in 400 µL Triton lysis buffer (1% 
Triton X-100 in Tris-buffered saline (TBS) with Roche Complete Mini Protease Inhibitor 
added) on ice for 15 minutes, then lysates were clarified by centrifugation at 16,100 x g 
for 20 minutes at 4ºC. Clarified lysates were added to 50 µL of PBS-washed anti-FLAG 
M2 agarose resin (Sigma) and rotated at 4ºC for 1 hour. Beads were washed 6x with 
TBS-T (Tris-buffered saline with 0.05% Tween-20). To elute bound proteins, 50 uL of 
100 ug/mL 3x FLAG peptide (Sigma) in TBS-T was added to the resin and rotated at 
4ºC for 20 minutes. Eluates were stored at -80ºC until further analysis. 
For MALDI-MS analysis, the entire protein sample was desalted using a C18 Sep 
Pak cartridge (HLB, 1cm3; 30mg, Oasis) and eluted in 50% acetonitrile. The sample was 
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dried in a SpeedVac, and then dissolved in a final volume of 10 µL mass spectrometry-
grade water (Burdick & Jackson). This solution (1 µL) was mixed with matrix (α-cyano-4-
hydroxycinnamic acid in 50% acetonitrile, 1 µL) on a stainless steel MALDI plate and 
air-dried. Data were acquired on a Waters MALDI micro MX instrument operated in 
linear positive mode. Instrument control and spectral acquisition were with MassLynx 
software.  
Confirmation of the FRAT2-SEP initiation codon, Kozak sequence, and bicistronic 
expression by immunoblotting: 
HEK293T cells were grown to 75% confluency in 6-well plates, then transfected with 10 
µg plasmid DNA using Lipofectamine 2000 according to the manufacturer’s instructions. 
Cells were harvested by vigorous pipetting and lysed in 100 µL Triton lysis buffer. 
Samples of clarified lysate (20 µL) were mixed with SDS-PAGE loading buffer, boiled, 
and electrophoresed on 4-20% Tris-HCl gels (Bio-Rad). Two replicate gels were run. 
Proteins were transferred to nitrocellulose (0.20 µm pore size, Thermo Scientific) and 
immunoblots were probed with anti-FLAG M2 antibody (Sigma) followed by goat anti-
mouse IR dye 800 conjugate (LICOR). For bicistronic expression assays, immunoblots 
were probed with a mixture of rabbit anti-c-myc antibody (Sigma) and anti-FLAG M2, 
followed by a mixture of goat anti-mouse IR dye 800 and goat anti-rabbit IR dye 680 
(LICOR). A replica immunoblot was probed with mouse anti-β-actin followed by goat 
anti-mouse IR dye 800. Antibodies were diluted 1:2000 in Rockland Immunochemicals 
fluorescent blocking buffer. Infrared imaging was performed on a LICOR Odyssey 
instrument. 
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4.1 Introduction 
 Our discovery of the prevalence of sORF-encoded peptides (SEPs) highlighted 
the extent to which the proteome is still unknown1.  Our peptidomics based pipeline 
made major strides in identifying SEPs1.  However, ribosome profiling and 
computational approaches suggested there were even more SEPs that our approach 
was failing to detect2,3.  This suggested that different methods could be used to identify 
an even larger number of SEPs. 
 When analyzing complex samples, mass spectrometry is stochastically limited.  
This biases discovery towards the most abundant species in a sample.  Therefore, it is 
plausible that a large number of SEPs could be missed by our mass spectrometry 
approach due to sample complexity.  Therefore, in order to further enrich SEPs from cell 
lysate, and in order to access a different pool of SEPs we developed a 
chemoproteomics approach. 
 Here, we apply a cysteine affinity enrichment approach to identify novel cysteine 
containing SEPs (ccSEPs).  Cysteine is the most reactive amino acid making it an ideal 
target for an affinity probe4.  Additionally, 92% of proteins are estimated to contain at 
least one cysteine implying that the many SEPs should have a cysteine available for 
labeling5. Furthermore, cysteine reactivity is governed by secondary structure and local 
environment, suggesting that enriching SEPs with highly reactive cysteines will likely 
favor the discovery of SEPs with distinct secondary structures4. Most importantly, by 
using a different strategy to enrich the peptidome, we anticipate the discovery of novel 
ccSEPs.  
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4.2 Isolation of Cysteine Containing SEPs 
Our strategy began with isolating the peptidome from K562 by lysis of these cells 
followed by a molecular weight cutoff (MWCO) filter to remove large proteins (Figure 1).  
We incubated the peptidome with a previously described iodoacetamide-alkyne (IA-
alkyne) probe that reacts with the sulfhydryl side chain of cysteine to form a covalent 
bond to the peptide1. After cysteine capture by IA-alkyne, the probe is conjugated to a 
biotin-labeled tobacco etch virus (TEV) recognition peptide through copper-activated 
click chemistry (CuACC)4,6,7.  Probe-labeled peptides are then separated from 
unlabeled peptides via streptavidin affinity chromatography to afford an enriched 
peptidome sample.  On-bead trypsin digestion was performed, and unlabeled peptides 
were eluted and analyzed by ERLIC-LC-MS/MS8. The labeled peptides were then 
removed from the beads by the addition of TEV protease. This fraction was then 
analyzed by MudPIT-LC-MS/MS9.  
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The data from this peptidomics analysis contains known as well as novel (i.e. 
non-annotated) peptides, including SEPs. In order to identify peptides originating from 
non-annotated RNAs, we created a custom database using K562 RNA-seq data1, which 
contains information on the vast majority of mRNAs in K562 cells. Since these RNAs 
must be the source of any polypeptide produced we can include non-annotated genes 
in our peptidomics search by simply translating this database in three frames to 
generate a protein database that contains all possible peptide products.  We then 
matched our peptide spectra against this RNA-seq database to reveal candidate SEPs.  
This approach yielded 175 hits that surpassed our preliminary Xcorr and deltaCN 
requirements6.  After removing annotated peptides we were left with 109 candidate 
 
 
Figure 4.1:  Workflow for identifying ccSEPs 
The proteome and peptidome are separated by a MWCO filter and the peptidome fraction is 
carried forward to identify ccSEPS. Incubation of the peptidome with an iodoacetamide-
alkyne (IA) probe leads to alkylation of cysteine-containing peptides including ccSEPs. 
Labeled peptides were then selectively enriched by conjugation to an azide-TEV-biotin tag 
using copper-activated click chemistry (CuACC) followed by affinity chromatography with 
streptavidin-coated beads. This sample is then analyzed by LC-MS/MS peptidomics and 
filtered to remove annotated proteins, which led to the identification of novel protein-
generating sORFs that produce ccSEPs.   
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SEPs.  Our K562-RNAseq database was too large to perform a reverse database 
search directly.  To overcome this, we constructed a forward and reversed database by 
appending our candidate SEPs to the human International Protein Index (IPI) database.  
We used this database to filter our candidate SEP spectra using a reversed database 
search, and only accepted peptides with a false discovery rate < 0.05.  Subsequently, 
we validated that detected peptides could only originate from a sORF.  Additionally, 
SEPs with more than 2 missed cleavages were removed along with SEPs detected from 
peptides fewer than 7 amino acids in length. Furthermore spectra were visually 
inspected to ensure good sequence coverage and confirm that peptides detected from 
the TEV fraction contained an IA-modified cysteine reside.   After this, we were left with 
17 novel human ccSEPs (Table 1).   
 
Table 4.1:  Detected peptides and the start codon and length (AUG or near 
cognate to stop) of their corresponding SEPs. 
 
aasterisk denotes probe labeled cysteine. 
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4.3 Validation of Cysteine SEP Labeling 
 
 To verify that our labeling and enrichment is specific to cysteine-containing 
SEPs, we performed an in vitro assay in cell lysates. We first synthesized TCT-SEP 
(named for the detected peptide; Table 1) by solid phase peptide synthesis, along with a 
mutant of this TCT-SEP where the cysteine is replaced by a serine, TST-SEP. We 
incubated TCT-SEP in K562 cell lysates and then added the IA-alkyne probe. After 
labeling, the lysate was mixed with a fluorescent azide in the presence of copper (II) 
sulfate and TCEP to promote CuACC.  This fluorescently labeled lysate was then 
resolved on an SDS page gel to assess labeling of the TCT-SEP. Labeling of TCT-SEP 
was specific and robust and could be easily observed within total K562 lysate (Figure 
2B). The control TST-SEP was not labeled when probe-treated alone or in K562 lysate 
demonstrating that labeling is occurring on the cysteine residue.  Additionally, in cases 
where a detected peptide contained multiple cysteines, the labeled cysteine could 
always be determined by MS/MS fragmentation along the peptide backbone (Figure 
3A).  
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 To validate the production of ccSEPs from their endogenous RNA, we 
transfected cells with a vector containing the sORF TSP-ccSEP, which is found on the 
same transcript as MRS2L. This construct contained the entire endogenous 5’UTR, 
which includes the sORF, and a FLAG tag was appended to the sORF to enable easy 
detection of protein production.  Stable ccSEP expression was then observed by 
immunofluorescence using an anti-FLAG antibody (green) (Fig 3C.).  This sORF was 
not annotated previously, thereby highlighting the ability of this workflow to discover 
novel protein-coding genes. More generally, this affinity strategy successfully identified 
a new pool of SEPs with characteristic hallmarks of this emerging class of peptides1.  
4.4 Novel ccSEPs 
 
 
Figure 4.2:  Validation of site of labeling and cellular expression of newly 
discovered ccSEPs. (A) In the case of ccSEPs with multiple cysteines, examination 
of the tandem MS spectra reveals the site of labeling. In this case, STS-ccSEP 
labels at the C terminal cysteine.  Red indicates fragments detected by y ions, blue 
indicates fragments detected by b ions, and purple indicates fragments detected by 
both.  (B) We tested labeling of one of the ccSEPs in a complex mixture by spiking 
the purified ccSEP into lysate and then performing a labeling reaction with 
rhodamine azide. If the ccSEP reacted it would fluorescently labeled.  Mutation of the 
cysteine on the ccSEP to a serine abrogates labeling. (C) A C-terminal Flag tag 
appended to the sORF coding for TSP-ccSEP validated that this sORF does indeed 
produce protein. Staining of the protein product with an anti-Flag antibody confirmed 
expression and cellular stability of the ccSEP. 
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 An overview of these newly identified ccSEPs revealed many similarities with 
previously identified SEPs. First, the length of their sORFs ranged between 16 and 97 
codons (Figure 2A). Second, these SEPs had both AUG start codons or non-canonical 
near cognate start codons (Figure 2B), similar to previously discovered SEPs. 
Moreover, SEPs could be found in the 3’UTR, frameshifted within known genes or 
within the 5’ UTR, in non-annotated RNAs, or in antisense transcripts (Supporting 
information).  All SEPs identified were fewer than 100 amino acids in length, and 
measuring sORF length as the stop codon to stop codon distance yielded a similar 
result.  These identified SEPs are very small relative to the average length of a human 
protein, which is 335 amino acids10. The small size of these SEPs contribute to the 
difficulties associated with computationally predicting the presence of these peptides. 
 While specific functions for these SEPs will require additional downstream 
experiments, we wanted to see if we could gain some insights about those SEPs that 
may be most useful to investigate moving forward. Sequence conservation is an 
important and well-documented signifier of biological  function11. We examined the 
conservation of our SEPs in several species by aligning in silico translated RNA.  Of the 
SEPs we discovered over one third (6/17) are conserved amongst several species 
alluding to their potential function.    Notably, the labeled cysteine residue does not vary 
between species, implying this residue may be important for the SEP’s biological 
function (Figure 3C).  Additionally, certain biologically important post translational 
modifications, such as protein S-nitrosylation, occur at, and can be regulated by, redox 
active cysteines12.  The conservation of ccSEPs, particularly at redox active cysteine 
and surrounding residues, raises the possibility that ccSEPs could have a role in 
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regulating the cellular redox state. The conservation of these SEPs makes them good 
leads for further functional characterization, and demonstrates that this platform allows 
for the identification of peptides that are of significant biological interest.  
          
 
 
Figure 4.3: ccSEP overview. (A) Distribution of ccSEPs by their length 
in amino acids. SEP length was determined using the distance from an 
upstream in frame AUG start codon to a downstream in frame stop 
codon, or, when no inframe AUG was present, a near cognate start 
codon or stop codon was used instead.  (B) While AUG is the 
predominant start codon for the production of ccSEPs, near congnate 
start codons (i.e. one base different from AUG) are also common. (C)  
TSP-SEP is strongly conserved amongst several species of primates 
suggesting this SEP may be functional.   
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4.5 Conclusion 
 In summary, we have utilized a chemoproteomics approach to identify new 
human ccSEPs.  These results demonstrate the value of chemoproteomics to promote 
the discovery of additional sORFs. In this case, we identified seventeen novel ccSEPs 
indicating the presence of even more of these molecules than had been predicted, and 
representing a 16% increase in the number of known SEPs. Moreover, conservation 
indicates that some of these ccSEPs may be functional.  The struggle to identify the 
whole range of SEPs in human cells as well as their functional role remains a key 
question in biology.  The development of mass spectrometry methods focused on the 
identification of SEPs, such as chemoproteomic approaches, is a critical step towards 
answering these questions.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
4.6 Methods 
Cell culture: 
Cells were grown at 37°C under an atmosphere of 5% CO2.  K562 cells were grown in 
RPMI 1640 medium with 10% FBS, penicillin and streptomycin.  Cells were maintained 
between 1-10 x 105 cells/ml.  HEK293T cells were grown in DMEM with 10% FBS, 
penicillin and streptomycin. 
Isolation of polypeptides: 
1x109 K562 cells were washed with ice cold PBS 3 times.  Cells were subsequently 
suspended in lysis buffer with 0.1M ammonium acetate, 0.5M NaCl, diprotin A (1 
ug/mL), antipain (1 ug/mL), leupeptin (1ug/mL), chymotrypsin (1 ug/mL) at pH 3.6 on 
ice.  Cells were sonicated on ice for 20 bursts with output level 2 using 30% duty cycle 
(Branson Sonifier 250).  Samples were then centrifuged at 3,000g for 10 min.  
Supernatant was collected and centrifuged through a 30kD molecular weight cutoff filter 
at 20,000g for one hour (Modified PES, Centrifugal Filter, VWR).  Filtrate was dialyzed 
into PBS, and polypeptide concentration was measured by BCA assay.  Cysteine 
containing SEPs were then enriched from this polypeptide sample for MudPIT-LC-
MS/MS analysis as described below. 
MudPIT-LC-MS/MS analysis: 
Probe-labeling, click chemistry, and streptavidin enrichment: 
Polypeptide samples were probe labeled with IA-alkyne (100 µM) for one hour at room 
temperature.  Probe-labeled samples were subjected to click chemistry. Biotin-TEV-azide 
(200 µM), TCEP (1 mM, 50X fresh stock in water), ligand (100 µM, 17X stock in DMSO:t-
Butanol 1:4), and copper(II) sulfate (1 mM, 50X stock in water) were added to the protein. 
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Samples were allowed to react at room temperature for 1 hour. Tubes were centrifuged 
(10 mins, 4°C) to pellet the precipitated proteins. The pellets were resuspended in cold 
MeOH by sonication. Centrifugation was followed by a second MeOH wash, after which 
the pellet was solubilized in PBS containing 1.2% SDS via sonication and heating (5 min, 
80°C). The SDS-solubilized, probe-labeled proteome samples were diluted with PBS (5 
mL) for a final SDS concentration of 0.2%. The solutions were incubated with 100 µL 
streptavidin-agarose beads (Thermo Scientific) at 4°C for 16 hrs. The solutions were then 
incubated at room temperature for 2.5 hrs. The beads were washed with 0.2% SDS/PBS 
(5 mL), PBS (3 x 5 mL), and water (3 x 5 mL). The beads were pelleted by centrifugation 
(1300 x g, 2 min) between washes. 
On-bead trypsin digestion: 
The washed beads were suspended in 6 M urea/PBS (500 µL) and 10 mM dithiothreitol 
(from 20X stock in water) and placed in a 65°C heat block for 15 mins. Iodoacetamide (20 
mM, from 50X stock in water) was then added and the samples were placed in the dark 
and allowed to react at room temperature for 30 mins. Following reduction and alkylation, 
the beads were pelleted by centrifugation (1300 x g, 2 min) and resuspended in 150 µL 
of 2 M urea/PBS, 1 mM CaCl2 (100X stock in water), and trypsin (2 µg). The digestion 
was allowed to proceed overnight at 37°C. The digestion was separated from the beads 
using a Micro Bio-Spin column (BioRad). The beads were washed with PBS (3 x 500 µL) 
and water (3 x 500 µL) to remove trypic peptides and urea. 
On-bead TEV digestion: 
The washed beads were resuspended in 150 µl of TEV digest buffer with AcTEV Protease 
(5 µl; Invitrogen) for 12 hr at 29°C with mild agitation. The eluted peptides were separated 
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from the beads using a Micro Bio-Spin column and the beads were washed twice with 75 
µl water, and washes were combined with eluted samples. Formic acid (15 µl) was added 
to the samples, which were stored at −20°C until mass spectrometry analysis. 
Offline electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) 
fractionation of peptides: 
ERLIC fractionation was performed offline prior to LC-MS/MS analysis using a PolyWax 
LP column (200 mm x 2.1 mm, 5µm, 300 Å, PolyLC Inc) connected to an Agilent 
Technologies 1200 Series HPLC equipped with a degasser and automatic fraction 
collector.  Runs were performed with a flow rate of 0.3 ml/min.  A 70 minute gradient 
beginning with 0.1% acetic acid in 90% acetonitrile and ending with 0.1% formic acid in 
30% acetonitrile was used, and eluant was collected in 4 fractions.  Fractions were 
evaporated to dryness before analysis by LC-MS/MS.  Samples fractionated by ERLIC 
were not fractionated by SCX, and were loaded directly onto a C18 column for analysis. 
Liquid chromatography-mass spectrometry (LC-MS) analysis: 
LC-MS analysis was performed on an LTQ Orbitrap Discovery mass spectrometer 
(ThermoFisher) coupled to an Agilent 1200 series HPLC. Digests were pressure loaded 
onto a 250 µm fused silica desalting column packed with 4 cm of Aqua C18 reverse phase 
resin (Phenomenex). The peptides were eluted onto a biphasic column (100 µm fused 
silica with a 5 µm tip, packed with 10 cm C18 and 3 cm Partisphere strong cation 
exchange resin (SCX, Whatman)). Using a gradient 5-100% Buffer B in Buffer A (Buffer 
A: 95% water, 5% acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% acetonitrile, 
0.1% formic acid). The peptides were eluted from the SCX onto the C18 resin and into 
the mass spectrometer following the four salt steps outlined in Weerapana et al6. The flow 
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rate through the column was set to ~0.25 µL/min and the spray voltage was set to 2.75 
kV. One full MS scan (400-1800 MW) was followed by 18 data dependent scans of the 
nth most intense ions with dynamic exclusion enabled. 
MS data analysis:  
The generated tandem MS data was searched using the SEQUEST algorithm against the 
databases listed in the main text. A static modification of +57 on Cys was specified to 
account for iodoacetamide alkylation, and a differential modification of 464.28596 was 
specified on Cys, corresponding to the IA-alkyne probe conjugated to the cleaved Biotin-
TEV-azide tag. The SEQUEST output files generated from the digests were filtered using 
DTASelect 2.0.  Samples with an XCorr score above 1.8 (+1), 2.5 (+2), 3.5 (+3) and 
deltaCN score above .08 were accepted.   
 Hits were then subjected to an iterative reverse database search.  A reverse 
database was constructed by appending sORF encoded peptide sequences, which 
coded for unannotated detected peptides to the human IPI database.  This database 
was reversed, and detected peptides were re-searched against the forward and 
reversed appended human IPI database.  A 5% FDR threshold was set.  
 Peptide hits were then searched against the human IPI database using a string 
matching algorithm and matches were removed.  Remaining hits were searched against 
the nonredundant protein database using Basic Local Alignment Search Tool (BLAST) 
and any peptides that matched known proteins were removed.  All detected peptides 
consisted of 7 or more amino acids.   
 Spectra of the remaining peptides were manually validated to ensure a precursor 
mass error of < 10 ppm.  Spectra also contained at least 5 sequential b or y ions, and 
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no more than 2 missed cleavages.  In the case of peptides identified from the biotin 
eluted fraction, all peptides were labeled with an iodoacetamide probe at a cysteine 
residue.   
SEP length was calculated using the length from the first AUG or near cognate 
start codon upstream of the detected peptide to the first stop codon downstream of the 
detected peptide.  SEP length could also be calculated using the length from the first 
AUG or stop codon upstream of the detected peptide to the first downstream stop codon 
 
 
 
 
  
109 
 
4.7 References 
 
(1) Slavoff, S. A.; Mitchell, A. J.; Schwaid, A. G.; Cabili, M.; Ma, J.; Levin, J. Z.; 
Budnik, B.; Rinn, J. L.; Saghatelian, A. Nature Chemical Biology 2012, 9, 59. 
 
 
(2) Ingolia, N. T.; Lareau, L. F.; Weissman, J. S. Cell 2011, 147, 789. 
 
 
(3) Stern-ginossar, N.; Weisburd, B.; Michalski, A.; Le, V. T. K.; Hein, M. Y.; Huang, 
S.; Ma, M.; Shen, B.; Qian, S.; Hengel, H.; Mann, M.; Ingolia, N. T.; Weissman, J. S. 
Science 2013, 338, 1088. 
 
 
(4) Weerapana, E.; Wang, C.; Simon, G.; Richter, F.; Khare, S.; Dillon, M. B. D.; 
Bachovchin, D. A.; Mowen, K.; Baker, D.; Cravatt, B. F. Nature 2010, 468, 790. 
 
 
(5) Miseta, A.; Csutora, P. Molecular Biology and Evolution 2000, 17, 1232. 
 
 
(6) Weerapana, E.; Speers, A. E.; Cravatt, B. F. Nature protocols 2007, 2, 1414. 
 
 
(7) Wu, P.; Feldman, A. K.; Nugent, A. K.; Hawker, C. J.; Scheel, A.; Voit, B.; Pyun, 
J.; Fréchet, J. M. J.; Sharpless, B. K.; Fokin, V. V. Angew. Chem. Int. Ed 2004, 43, 
3928. 
 
 
(8) Alpert, A. Anal. Chem. 2008, 80, 62. 
 
 
(9) Washburn, M.; Wolters, D.; Yates, J. Nature biotechnology 2001, 19, 242. 
 
 
(10) Ota, T.; Suzuki, Y.; Nishikawa, T.; Otsuki, T.; Sugiyama, T.; Irie, R.; Wakamatsu, 
A.; Hayashi, K.; Sato, H.; Nagai, K.; al., e. Nature Genetics 2004, 36, 40. 
 
 
(11) Ponjavic, J.; Ponting, C.; Lunter, G. Genome Res 2007, 17, 556. 
 
 
(12) Hess, D. T.; Matsumoto, A.; Kim, S.; Marshall, H. E.; Stamler, J. S. Nature 
Reviews Molecullar Cell Biology 2005, 6, 150. 
110 
 
 
 
 
 
 
 
 
 
Chapter 5:  Functional Characterization of sORF-Encoded Peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aravind Subramanian, Willis Read-Button, and Ted Natoli measured the L1000 data.  
Rajiv Narayan processed and Z-scored the L1000 data.  I prepared samples for L1000 
measurement, performed downstream bioinformatic analysis, and performed all other 
experiments. 
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5.1 Introduction
 
 Mass spectrometry and ribosome profiling methods have successfully been used 
to identify sORF-encoding polypeptides (SEPs)1,2.  These studies have unequivocally 
demonstrated widespread translation from non-annotated sORFs, and therefore SEPs 
represent the cells protein ‘dark matter’.  Additionally, evidence of translation from non-
AUG start codons implies the proteome is larger and more complicated than 
imagined1,3.  In light of these discoveries, a major challenge moving forward is the 
determination of the functions of these SEPs, if any, in cells and/or tissues.  
 A handful of SEPs have been found to be functional in other species and one has 
been found in humans.  The eleven amino acid peptide encoded by the Tal gene is 
necessary for proper morphogenesis in Drosophila4.  Tal is a polycistronic mRNA that 
encodes three 11 and one 32 amino acid long peptides5.  These peptides were found to 
interact with filamentous actin and are involved in denticle formation.  In the absence of 
the tal gene, or when the sORFs are frameshifted, apical cuticular structures are 
completely eliminated.  These examples highlight the importance of SEPs in fly 
morphogensis, and also highlight the misannotation of key genes as non-coding RNAs.   
A bioactive SEP has also been found in human cells.  Humanin, a 24-amino acid 
peptide, was shown to inhibit neuronal cell death induced by familial Alzheimer’s 
disease mutant genes and amyloid-β (Aβ)6,7.  Using yeast two hybrid assays, it was 
determined that humanin mediated these functions by interacting with insulin-like growth 
factor-binding protein 38, and cell biology has determined that humanin operates by 
inhibiting the function of the pro-apoptotic BAX.  Of course, these SEPs were 
discovered through functional screens and therefore it still remains to be determined 
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whether any of the SEPs discovered through LC-MS profiling, or ribosome profiling for 
that matter, are actually functional.  
 It has been suggested that SEPs are involved in de novo gene birth, and are in 
fact proto-genes9.  This theory suggests that translation of sORFs to SEPs is a way of 
sampling non-genic regions of the genome for peptides that confer an adaptive 
advantage.  Presumably, such peptides would be selected for and eventually evolve 
into more strongly conserved genes.  This is a compelling hypothesis, but it is possible 
that sORFs could prove advantageous without evolving into longer genes.  This 
suggests the possibility that sORFs themselves could have function, and emphasizes 
the need to develop systematic tools to understand SEP function in order to fully 
understand the biology SEPs may regulate.   
 The need to systematically understand whether or not a class of biomolecules is 
functional and what its function may be is not a new one.  Guttman et al. faced this 
challenge when confronting the discovery of the existence of thousands of long 
intergenic noncoding RNAs (lincRNAs)10.  In order to determine whether or not these 
molecules are functional and to assign them putative functions, they developed a 
strategy dependent on measuring changes in gene expression.  In particular, they used 
DNA microarrays to analyze lincRNA levels in different cellular or tissue contexts.  For 
instance, Guttman and coworkers looked at lincRNA levels over a time course of 
embryonic tissue development, in different adult tissues (brain, lung, ovary, and testis), 
and in several cell lines (mouse ESCs, NPC, MEF, and MLF).  They then categorized 
expression levels in these tissue and cell types, and correlated lincRNA levels to these 
categories.  This allowed them to assign lincRNAs into basic Gene Ontology 
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categories11.  Additionally, they could validate some of these putative assignments.  For 
example, they treated p53+/+ and p53-/-  MEFs with a DNA damaging agent and 
observed that lincRNAs they had assigned to the category of “p53-mediated damage 
response” were significantly elevated in the p53+/+ but not p53-/-  MEFs.  This strategy 
successfully demonstrated lincRNAs were functional and hinted at their possible cellular 
functions.  On its face, a similar strategy could be used to understand SEPs.  In order to 
systemically screen for SEP bioactivity, and gain insights into SEP function we have 
developed a causative transcriptomics-based pipeline to characterize SEPs (Figure 
5.1). 
 
 
5.2  SEPs alter gene expression             
 
 
Figure 5.1:  Platform for functionally characterizing SEPs.  In order to 
functionally characterize SEPs we screened for changes in gene expression upon 
SEP overexpression.  The most interesting cases could then be validated by qPCR.  
Changes in gene expression could be mapped to pathways using gene set 
enrichment analysis (GSEA).  This yielded a putative cellular role for the SEPs, 
which could be further characterized biochemically and these changes could be 
ascribed to a biological function. 
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 Changes in gene expression upon knockdown or overexpression of a protein are 
one possible signifier of function.  Since SEPs are frequently bicistronic1 it is often 
impossible to knockdown the SEP without knocking down an annotated protein coding 
gene.  This would greatly complicate any interpretation of changes in gene expression.  
In order to simplify data interpretation, and ensure changes in gene expression are a 
result of changes in SEP expression we opted to increase cellular SEP levels in order to 
determine whether or not SEPs effected gene expression.  Moreover, since all known 
SEPs are thought to be intracellular and SEPs are too large to pass through the cell 
membrane we chose to recombinantly overexpress SEPs within the cell.   
 We transiently transfected a vector coding for flag tagged SEPs in HEK293T 
cells.  The presence of a flag tag allowed us to confirm translation and expression of 
SEPs via immunofluorescence.  As a control, HEK293T cells were transfected with an 
empty vector.  Afterwards, cells were lysed, mRNA was harvested, and gene 
expression levels were measured with a streamlined microarray technology called 
L1000. 
 L1000 is a method for quickly and cheaply measuring the transcript levels of 
1,000 genes, and computationally inferring the transcript levels of an additional 21,000 
genes12.  Using this method, mRNA is reverse transcribed to cDNA.  cDNA is then 
annealed and ligated to upstream and downstream probes which contain gene specific 
sequences, an oligonucleotide “barcode”, and  upstream and downstream primer sites.  
The ligated product is then amplified, and the 5’ end is conjugated to biotin.  Fluorescent 
microspheres conjugated to oligonucleotides are annealed to the DNA “barcode”, and 
amplicons are immobilized.  The fluorescence of the annealed microspheres is 
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measured, and the fluorescence intensity is proportional to the abundance of transcripts 
of the gene complementary to the gene specific probes.  This approach can be 
simultaneously applied to 1000 transcripts to directly measure their abundance.  
Subsequently, using inferential models developed at the Broad Institute the expression 
levels of an additional 21,000 genes can be estimated.  L1000 is a critical technique for 
measuring expression levels in response to SEP treatment.  Although DNA microarrays 
would provide similar data, this method lacks the throughput and affordability of L1000.  
Using this technique allowed for the gene expression levels of many SEP treated 
samples to be measured. 
 Using this approach we measured changes in gene expression after treatment 
with 20 different SEPs.  Of these SEPs, 17 resulted in significant changes in gene 
expression and three did not though they were expressed. Thus, not all SEPs regulate 
transcription. Gene expression changes were determined to be significant if they 
surpassed a rigorous threshold of repeatability and signal strength.  Namely, gene 
expression signatures had to have a pairwise spearman correlation coefficient of ≥ 0.2 
within the 75th percentile, and a signal strength score of ≥ 4 where this number was 
computed as the difference in means between the top and bottom 50 most differentially 
expressed genes.   
To illustrate the strength of these gene expression changes, cells were also 
treated with a variety of small molecule signal calibrators (Figure 5.2).  These calibrators 
included wortmanin, a kinase inhibitor, geldanamycin, an HSP90 inhibitor, and HDAC 
inhibitors Vornistat and Trichostatin A13-16.  Most SEPs induced gene expression 
changes similar in magnitude to treatment with wortmanin, which inhibits 
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phosphotidylinositide 3-kinases (PI3Ks)13.  One SEP induced gene expression changes 
similar in magnitude to inhibition of HSP90 with gelandamycin, which leads to 
degradation of p5314.  Two SEPs induced gene expression changes even larger than 
this, although they did not induce changes in the same range as treatment with HDAC 
inhibitors15,16.  These changes in gene expression indicate SEP expression has a strong 
effect on gene expression, and demonstrates that the majority of SEPs are able to 
effect gene expression levels, which suggests SEPs may have important roles within 
the cell. 
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Figure 5.2:  Signal strength and repeatability of gene expression changes 
induced by SEPs.  Signal strength was calculated as the mean difference in 
expression of the top 50 and bottom 50 compared to the control.  Repeatability is 
indicated by the Spearman Correlation Coefficient within the 75th percentile.  Cells 
expressing SEPs were compared to cells transfected with vectors bearing the SEP 
sORF but lacking an initiation codon or to cells treated with pcDNA3.  Additionally, 
cells were treated with trichostatin A, vornistat, HSP90, or wortmannin as signal 
strength calibrators.   
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 Changes in gene expression upon SEP treatment were specific (Figure 5.3).  
Genes whose expression levels were affected by one SEP were not affected by 
 
Figure 5.3:  Marker analysis indicates SEPs induce specific gene expression 
changes.  Analysis of the top 10 most highly induced genes upon SEP expression 
demonstrates C7orf49 regulates different genes than PHF19-SEP, DNLZ-SEP, or 
DEDD2-SEP.  Likewise, the most highly induced genes upon PHF19 expression 
are not induced by C7orf49-SEP, PHF19-SEP, DNLZ-SEP, and DEDD2-SEP.  This 
indicates gene expression changes are specific to the SEP polypeptide sequence. 
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another.  Marker analysis, where the top ten most overexpressed and under expressed 
genes are analyzed, indicated no pattern in gene regulation between different SEPs.  
Moreover, gene set enrichment analysis (GSEA) performed between SEPs 
demonstrated no overlap (Figure 5.4)17.  This indicates that SEP induced changes in 
gene expression are not a broad cellular response to overexpression of peptide and are 
rather an exclusive effect induced by the amino acid sequence of each particular SEP.   
 
 Another possibility is that changes in gene expression are due to changes  at the 
RNA level.  Namely, that expression of the sORF RNA, but not the SEP itself resulted in 
regulation of gene expression.  To eliminate this possibility, the start codon was 
eliminated from 14 out of 20 sORFs and a vector coding for this non translatable sORF 
was transfected in place of an empty vector.  In the 14 cases analyzed ablation of the 
start codon was found to eliminate translation of the sORF.  However, in 4 additional 
cases ablation of the putative start codon did not eliminate translation.  In these cases it 
is possible a truncated SEP is produced from alternate start codons within the sORF.  
Notably, this is consistent with ribosome profiling data, which indicates a single sORF 
 
Fig 5.4:  Gene set enrichment analysis indicates SEPs induce specific 
gene expression changes.  Gene expression changes induced by EIF5-SEP 
were compared to gene sets comprising the top 50 most upregulated genes 
upon DEDD2-SEP, MCG16703-SEP, PHF19-SEP, or C19orf29SEP 
expression.  None of them matched further supporting that SEPs induce 
different gene expression changes from one another.  
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can initiate with multiple start codons2.  Comparison between vectors encoding SEPs 
and vectors encoding non-translatable SEPs demonstrated that changes in gene 
expression were dependent on SEP translation indicating gene expression is regulated 
at the peptide, not the RNA level (Figure 5.2).  Together, these experiments 
demonstrate that SEPs regulate gene expression, and present the first evidence that 
SEPs, as a class of biomolecules, are bioactive. 
5.3 SEPs can be assigned to putative cellular processes 
 
 Changes in gene expression can be related to biological phenomena through a 
variety of conceptual techniques including hierarchal clustering, marker analysis, and 
gene set enrichment analysis (GSEA) amongst others17.  In order to interpret the 
biological significance of SEP induced changes in gene expression, we used GSEA to 
match changes in gene expression to putative pathways and processes.  This method 
provides a robust and straight-forward route to biological characterization.  GSEA allows 
one to compare changes in expression data to known grouping of genes that are up or 
downregulated in a particular process.  These groupings are called gene sets, and can 
be relatively simple—such as a group of genes categorized in a Gene Ontology defined 
process—or can be more complicated such as gene changes observed upon cellular 
treatment with perturbogens.  Using GSEA gene expression changes stimulated by 
SEPs could be analyzed. 
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 SEPs were mapped to basic cellular processes and pathways by means of 
GSEA against Gene Ontology gene sets (Figure 5.5).  This analysis was successful at 
assigning putative pathways or cellular processes for 16/17 SEPs.  The remaining SEP 
did not provoke gene expression changes that fell neatly within a Gene Ontology 
category.  However, gene expression changes induced by this SEP could be mapped to 
gene expression changes induced by various perturbogens, or present in certain tissue 
states.  Thus, although this SEP may not have a clear role in any single pathway it does 
regulate genes involved in various cellular processes.   
 The 16 SEPs that mapped distinctly to particular cellular processes fell into 
several different categories.  In particular, SEPs were involved in protein processing, 
DNA binding and transcription, cell cycle and migration, signaling, translation, and 
pathways involved in hydrolysis or redox.  Interestingly, SEPs did not appear to be 
involved in a single sphere of biology, but rather were involved with numerous unrelated 
pathways.  This suggests that SEPs are involved in disparate processes.  This implies 
 
Figure 5.5:  SEPs are involved in cellular pathways.  SEP induced gene 
expression changes can be mapped to putative pathways by using gene set 
enrichment analysis to match expression profiles to Gene Ontology gene sets.  
Similar to an assortment of unrelated proteins, SEPs were involved in a variety of 
different pathways.   
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SEPs are important in a broad range of biological processes, as is the case for known 
proteins. 
5.4 eIF5-SEP is involved in inflammation 
  
 Expression of eIF5-SEP resulted in a signal strength score of 12.9, indicating 
larger gene expression than any other SEP.  Gene expression changes induced by 
eIF5-SEP were dramatic, and were substantially higher than gene expression changes 
induced by inhibiting PI3Ks which had a signal strength score of 6.7 or HSP90 which 
had a signal strength score of 11.3.  We validated changes in several of the genes 
observed to change in the presence of eIF5-SEP L1000 by qPCR (Figure 5.6).  The 
magnitude of these changes suggested eIF5-SEP may have an important role in biology 
and merited further study. 
 
 In order to understand at a detailed level what effect eIF5-SEP may have on cell 
biology we compared the gene expression profile of eIF5-SEP treated cells to a 
database of chemical and genetic perturbations gene sets.  In these gene sets cells or 
 
Figure 5.6:  QPCR validates eIF5-SEP gene expression changes.  We validated 
the expression of 3 genes indicated to be highly expressed in the L1000 data using 
qpcr.  Statistics was performed with a Student’s t-test, *, p ≤ 0.05.  One tailed t-test 
was used to confirm the one directional hypothesis developed from the L1000 data. 
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tissues are perturbed and changes in gene expression are measured.  These changes 
are stored as a gene set.  For instance, cells could be treated with a small molecule, or 
UV light, and changes in gene expression after treatment could be measured and 
stored.  Additionally, gene expression in cells with abnormal genetic backgrounds—
such as cancer cells—can be catalogued.   
This analysis revealed that eIF5-SEP expression regulated genes also regulated 
by treatment with TNFα18,19.  That is, genes overexpressed when cells are treated with 
TNFα were also overexpressed when cells overexpressed eIF5-SEP.  This result 
indicates that, like TNFα, eIF5-SEP is involved in inflammation (Figure 5.7).  Moreover, 
of the 19 other SEPs examined for changes in gene expression only one, TRIM41-
SEPmapped to similar gene sets indicating these changes in gene expression are 
specific to eIF5-SEP.  Notably, the genes eIF5-SEP activates are downstream of NF-κB, 
and NF- κB itself is overexpressed in the presence of eIF5-SEP (Figure 5.7).   
Interestingly, when matched against Gene Ontology gene sets (which do not 
contain a NF- κB geneset) eIF5-SEP matched most strongly to genes involved in 
cellular redox activity.  The redox state of the cell is an important determinant for NF-κB 
activity, and can effect NF- κB translocation into the nucleus and subsequent DNA 
binding20.  In turn, NF- κB can influence the redox state of the cell by inducing 
transcription of ferritin heavy chain (FHC1) and superoxide dismutase 2 (SOD2)21.  This 
suggests the possibility that eIF5-SEP is effecting NF-κB target gene expression by 
altering the redox state of the cell, although could also be interpreted as a change in the 
cellular redox state first induced by eIF5-SEP stimulation of NF-κB target gene 
expression.  In contrast, TRIM41-SEP triggered genes involved in protein kinase 
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signaling suggesting that although stimulation with eIF5-SEP and TRIM41-SEP may 
have similar outcomes they operate through different mechanisms.     Regardless of 
precisely how eIF5-SEP induces changes in NF- κB target gene expression, these 
changes provide a strong indication that eIF5-SEP has a role in inflammation through 
activation of the NF- κB pathway.  
 
 
 
Figure 5.7  eIF5-SEP induces expression of pro-inflammatory genes.  Gene 
expression changes induced by EIF5-SEP mapped to gene expression changes 
induced by TNFα.  In particular, EIF5-SEP induced expression of NF-κB and NF-κB 
genes, which are involved in inflammation.    
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 Interleukins are a key intercellular regulator of inflammation22.  Furthermore, 
certain interleukins are known to be upregulated upon treatment with TNFα, which 
stimulates NF-κB23.  In order to see whether or not overexpression of eIF5-SEP was 
consistent with TNFα treatment at the protein level, and also whether or not eIF5-SEP 
treatment resulted in higher levels of proinflammatory proteins, we performed an ELISA 
to measure interleukin 8 levels (IL-8), and found that HEK293T cells transfected with 
eIF5-SEP secreted 2.6 fold more IL-8 as compared to control (Figure 5.8).  IL-8 is a 
cytokine and chemotactic agent for lymphocytes and neutrophils24.  Its expression also 
induces angiogenesis, and it has a well described role in acute inflammation25,26.  
Increase in IL-8 levels upon EIF5-SEP treatment is a strong indicator that EIF5-SEP is 
involved in inflammation.   
 
Figure 5.8:  eIF5-SEP induces expression of IL-8.  Media from cells transfected 
with eIF5-SEP had much higher levels of IL-8 than media from cells transfected with 
pcdna3 as measured by ELISA.  IL-8 is a key mediator of inflammation supporting the 
role of EIF5-SEP in inflammation.  Statistics was performed with a Student’s t-test, *, p 
≤ 0.05. 
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 Changes in IL-8 levels were consistent at the genetic level as well.  L1000 results 
indicated highly upregulated transcription of IL-8 RNA upon eIF5-SEP stimulation 
(Figure 5.9).  Moreover, stimulation with other SEPs did not affect IL-8 RNA levels.  This 
indicates that pro-inflammatory effects of eIF5-SEP are particular to this SEP.   
 
Figure 5.9:  IL-8 RNA expression.  eIF5-SEP, but not ZNF524-SEP, or ADAMTSL4-
SEP induces expression of IL-8 RNA.  This measurement is a Z-score derived from 
L1000 experiments. 
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 Pro-inflammatory signaling can also be triggered by changes at the metabolite 
level.  Global metabolite profiling of cells after transfection with vector coding for eIF5-
SEP indicated upregulation of a phosphatidic acid with a mass corresponding to 
20:4/20:1 phosphatidic acid and arachidonic acid (Figure 5.10).  Arachidonic acid is a 
pro-inflammatory metabolite known to be upregulated upon TNFα treatment that can be 
metabolized to leukotrienes, prostaglandins and thromboxanes27,28.  Phosphatidic acid 
is a precursor to arachidonic acid and can therefore be involved in inflammation as well.  
In the presence of cytosolic phospholipase A2 (PLA2), which is upregulated in cells 
treated with eIF5-SEP or TNFα, the 20:4 fatty acid of phosphatidic acid is hydrolyzed 
from the glycerol backbone resulting in the formation of arachidonic acid, and thus 
 
Figure 5.10:  eIF5-SEP upregulates pro-inflammatory metabolites.  Cellular lipid 
levels were analyzed upon eIF5-SEP transfection by LC-MS using a lipidomics 
approach.  This approach demonstrated elevated levels of pro-inflammatory 
metabolites, phosphatidic acid, and arachidonic acid.  The phosphatidic acid exact 
mass corresponds to 20:1/20:4 phosphatidic acid. Statistics was performed with a 
Student’s t-test, *, p ≤ 0.05. 
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contributes to proinflammatory signaling29.  These results are consistent with a 
proinflammatory role for eIF5-SEP. 
 Expression of eIF5-SEP results in changes at the RNA, protein, and metabolite 
level that are all consistent with a pro-inflammatory role.  Moreover, changes induced by 
eIF5-SEP mimic pro-inflammatory changes induced by TNFα.  This evidence clearly 
points to eIF5-SEP as an important peptide in inflammation. 
5.5 eIF5-SEP regulation                   
    
 eIF5-SEP is located within the 5’UTR of another gene, elongation initiation factor 
5 (eIF5).  Previously, we have demonstrated that some SEPs are expressed 
bicistronically1.  However in the case of bicistronic 5’UTR SEP expression, expression 
initiated with an alternate start codon, and leaky translation of the 5’ ORF allowed for 
translation of the downstream gene.  However, eIF5-SEP initiates with an AUG start 
codon, and, though frameshifted, overlaps with eIF5.  This would seem to down-
regulate or prevent translation of the downstream eIF5 gene1,30,31.   
 eIF5 is a component of the ribosome, and after the 40S ribosome subunit has 
bound to a start codon, eIF5 mediates joining of the 40S and 60S ribosome subunits 
and hydrolysis of GTP bound to eIF232.  Thus, eIF5 is necessary for cell growth and 
viability33,34.  Therefore, the organization of eIF5-SEP and eIF5 posed the question of 
how both of these genes could be translated. 
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 Annotated transcripts of eIF5 indicate two transcript variants, one containing both 
eIF5-SEP and eIF5, and another transcript with a truncated 5’ UTR that only encodes 
eIF5 (Figure 5.11)35,36.  The presence of this second transcript explains how eIF5 is 
translated.  However, it appeared eIF5-SEP could only be translated from the first 
transcript variant.  This implied eIF5-SEP is coregulated with eIF5.  This was surprising, 
since these two genes do not appear to share any common function. Therefore, in order 
to more fully understand how eIF5-SEP is translated we performed RACE-PCR to 
identify any unannotated transcript variants of this gene.  Notably, we discovered a 
transcript with a truncated 3’UTR.  This transcript encodes the eIF5-SEP, and does not 
code for the full length eIF5 gene.  Thus, eIF5-SEP and eIF5 are both able to be 
 
Figure 5.11:  RACE PCR illustrates a mechanism of EIF5, EIF5-SEP translation.  
Rapid amplification of cDNA ends (RACE) using forward and reverse gene specific 
probes for EIF5-SEP detected an unidentified transcript, which contains the EIF5-SEP 
sORF and truncated EIF5.  The 3’ end of EIF5 is truncated and encodes only 161/431 
codons of EIF5, although the entirety of EIF5-SEP is encoded.  This provides a 
mechanism for how both EIF5 and EIF5-SEP can be translated even though their coding 
sequences overlap one another.   
RefSeq Variant 1
RefSeq Variant 2
RNA-Seq Transcript
RACE Variant
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translated as they are encoded on separate transcripts.  This data presents an alternate 
mechanism of regulation of 5’ sORF translation in addition to bicistronic translation, and 
demonstrates a means by which eIF5-SEP can be expressed without coregulation of 
eIF5 at the translational level. 
5.6 Conclusion 
 
 In this chapter we were able to develop a transcriptomics based pipeline, which 
revealed that SEPs are bioactive, and identified one SEP that has a significant role in 
inflammation.  This approach allowed us to characterize a class of molecules with no a 
priori knowledge of their function, or whether indeed they had any function at all.  
Moreover, this approach allowed us to screen for molecules that induced the most 
significant cellular changes and allowed us to develop a lead for follow-up biological 
characterization.  The success of this approach allowed us to make major strides in 
understanding the biological role of sORF peptides.   
 An unresolved question regarding SEPs biological function is their apparent 
coregulation with annotated proteins.  Since many SEPs are located on the same 
transcript as annotated genes, and translated bicistronically many SEPs must be 
coregulated with known genes at least at the RNA level.  As the study of SEPs moves 
forward, the purpose of this coregulation stands out as a tantalizing question.  On one 
hand, encoding two ORFs in close proximity could merely be a way to incorporate the 
maximum amount of information in a minimal amount of space, or could arise by chance 
as functional sORFs evolve from proto-genes.  Another explanation is that the two 
ORFs regulate the same process, or are expressed in response to the same stimulus.  
A key difficulty in answering this question is that it requires the complete functional 
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characterization of both SEP and protein.  However, from our transcriptomics based 
approach it does not appear that this is likely, since the genetic signature induced by 
SEP stimulation does not overlap with the known functions of proximal genes.  As the 
function of the proteome becomes more fully understood it will be exciting to see how 
the answer to this question unfolds. 
 Ultimately the fusion of mass spectrometry and transcriptomics based 
approaches has allowed for the discovery of a new class of functional biomolecules.  
Moreover, this approach has made inroads into understanding exactly how SEPs affect 
biology.  These discoveries highlight that, although the Human Genome Project was 
completed a decade ago, the complexity and breadth of the proteome it encodes is still 
not fully known.  The discovery and characterization of SEPs open new avenues to 
explore, and will allow us to understand biology at a deeper level.       
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5.6 Methods: 
 
Cell Culture: 
HEK293T cells were grown in DMEM with 10% FBS and penicllin/streptomycin.  Cells 
were grown at 37°C with a 5% CO2 atmosphere.  
L1000 Transfection: 
Cells were transfected at 70% confluency with 250ng plasmid DNA and .5uL 
lipofectamine 2000 in optimem.  10, 20, or 30 hours later cells were harvested.  To 
harvest cells, media was aspirated and replaced with 100uL TCL buffer (qiagen) gently 
rocked for 30 minutes, then covered and frozen at -80°C until measurement. 
L1000 Measurement: 
The L1000 measurement was performed as reported in Peck et al.12 
Bioinformatics: 
Bioinformatic analysis was performed with the Gene-E software and Msigdb 
software freely available on the Broad’s website 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp)  In order to categorize SEPs into 
putative cellular pathways GSEA was run against the c5 Gene Ontology data set.  In 
order to assign more specific functions to SEPs GSEA was run against the c2 dataset.  
Both datasets are freely available at 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp and 
http://www.broadinstitute.org/cancer/software/GENE-E/) 
Heat maps were made in Gene-E software suite, where SEP signal strength is 
determined as a function of the signal strength of the well compared to the average 
signal strength of the plate as background.  GSEAs were conducted using a preranked 
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list, ranked by Z-score.  Z-score was determined by ().  For gene set matches, only 
matches with an FDR≤.05 and p value≤.05.  SEPs were assigned to putative pathways 
based upon the geneset with the highest normalized enrichment score from a GSEA 
versus the c5 Gene Ontology gene set.  Positive phenotype matches were given priority 
to negative phenotype matches, since this simplifies downstream interpretation.   
QPCR: 
QPCR was conducted with the qiagen quantitect reverse transcription kit and qiagen 
quantitect SYBR green kit according to the manufacturer’s instructions.  Primers were: 
GAPDH: GGCTCTCCAGAACATCATCCCTGC 
GAPDH: GGGTGTCGCTGTTGAAGTCAGAGG 
NFKB: CCTGGCAGGTCTACTGGAGG 
NFKB: AAATAGGTGGGGACGCTGT 
CDKN1A: GGAGGCGCCATGTCAGAACCGGCT  
CDKN1A: GCCATTAGCGCATCACAGTCGCGGCTC 
GADD45B:  ACATGACGCTGGAAGAGCTCGTGGCG           
ELISA: 
IL-8 ELISA was performed using a kit from invitrogen according to the manufacturer’s 
instructions 
Metabolite Profiling: 
10cm dishes were transfected with plasmid coding for EIF5-SEP or pcdna3.  Twenty 
four hours later, cells were washed and harvested.  Cells were extracted into 2:1:1 
chloroform:methanol:media.  The chloroform layer was dried under nitrogen and then 
lipids were redissolved in 200uL chloroform. 80uL was injected on LC-MS TOF in 
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positive and negative mode.  Chromatograms were then aligned using XCMS in order to 
identify lipids that were changing.  In order to confirm the identity of arachidonic acid, 
this ion was coeluted with an arachidonic acid standard.  Phosphatidic acid identity was 
confirmed by LC-MS/MS. 
RACE pcr: 
Race pcr was performed with in the 5’ and 3’ direction using the GeneRacer kit and the 
following gene specific primers:  
1:  tcaaccgcagcgtgtcagaccagttcta 
2:  ccgcagcgtgtcagaccagttctatcgc 
3:  tagaactggtctgacacgctgcggttga 
4:  gcgatagaactggtctgacacgctgcgg 
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Appendix: 
 
A.1 Experiments to identify bioactive lipids in cancer and inflammation 
 
A.1.1 Discovery of osteoclast secreted lipids that promote bone cancer 
metastasis. 
 In bone cancers, osteoclasts have been tied to increased cancer metastasis and 
tumor growth1.  Interactions in the tumor microenvironment between osteoclasts and 
cancer cells can lead to both osteolysis and tumor proliferation1.  In particular, 
osteolysis leads to the secretion of bone derived growth factors, such as insulin-like 
growth factor 1 (IGF1), and transforming growth factor-β (TGF-β), and raises 
extracellular calcium ion levels.  IGF1 and TGF-β are recognized by receptors on the 
tumor cell and trigger downstream phosphorylation through the MAPK and SMAD 
pathways triggering growth.  Extracellular calcium levels activate the calcium pump and 
also contribute to tumor growth.  In turn, tumor cells secrete parathyroid hormone 
related peptide (PTHrP), which promotes osteoclast differentiation—completing the 
positive feedback loop.   
 Peroxisome proliferator-activated-receptor ɤ (PPARɤ) is also important in 
osteoclast differentiation and bone resorption2.  Agonism of PPARɤ with rosiglitazone, a 
PPARɤ ligand, promotes osteoclastogenesis and breakdown of bone.  PPARɤ 
activation can also lead to changes in lipid metabolism3.   
 In addition to the secretion of tumorigenic protein hormones there is also the 
possibility that osteoclasts secrete pro-tumorigenic lipids.  Therefore, osteoclasts were 
treated with or without rosiglitazone in order to promote osteoclastogenesis, bone 
resorption, and accentuate lipid production from macrophages4.  Media secreted from 
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treated or untreated osteoclast was collected, lipids were extracted, and were analyzed 
using a global LC-MS approach.   This method indicated a number of up and down 
regulated metabolites (Figure A.1).  Coelution with synthetic standards was used to 
confirm upregulation of polyunsaturated fatty acids including ω-6 arachidonic acid, and 
eicosopentanoic acid, while MRM analysis confirmed that phosphatidylcholines (PC) 
were downregulated.  Notably both arachidonic and eicosopentanoic acid are 
proinflammatory metabolite precursors.   The effect of these lipids on cancer cell 
proliferation is being investigated further. 
 
A.1.2 Identification of abnormal lipids levels in alopecia inducing mouse milk   
 Adiponectin is a cytokine secreted principally by adipocytes that has been shown 
to regulate lipid metabolism and homeostasis5.  Recently it was found that knock-out 
 
Figure A.1:  Lipids up or down regulated in rosiglitazone treated or control 
osteoclast.  ω-6 arachidonic acid and eicosopentanoic acid were verified by 
coelution.  PCs were verified by MRM.  Statistics was performed with a Student’s t-
test, *, p ≤ 0.05, **, p ≤ 0.01. 
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mice lacking adiponectin, or transgenic mice overexpressing adiponectin produced milk 
that induced alopecia in pups.  Lipids, and in turn adiponectin, can have 
proinflammatory functions, and in order to determine how effecting adiponectin levels 
was triggering alopecia, lipids in knock out (KO), transgenic (TG), and wild type (WT) 
mouse milk were examined6.  A global lipid profiling approach revealed that adiponectin 
KO mouse milk lacked lysoPCs, relative to WT milk (Figure A.2 and A.3).  Additionally, 
neutral loss mass spectrometry of triglyceride species revealed that certain triglycerides 
were depleted in KO and TG mice.  The role of these lipids in alopecia merits further 
study.  
 
 
Figure A.2:  LysoPCs are downregulated in the milk of adiponectin KO mice.  Changes in 
lysoPCs were identified using a global lipidomics approach.  The identity of some lysoPCs was 
further validated by MRM.  Statistics was performed with a Student’s t-test, *, p ≤ 0.05. 
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Figure A.3:  Triglyceride levles in adiponectin KO and TG mouse milk.  (Top)  
Although the most abundant triglycerides are unchanged in KO and TG milk, several 
less abundant triglycerides are depleted compared to WT.  (Bottom)  Close up of 
changes in C20:4, C20:2, and C20:1 triglycerides illustrates the depletion of these 
triglycerides relative to the WT sample.  Statistics was performed with a Student’s t-
test, *, p ≤ 0.05 
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Table A.1:  Complete list of SEP detected peptides and validation methods used to 
confirm them from chapter 3. 
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(Continued) Table A.1:  Complete list of SEP detected peptides and validation methods 
used to confirm them from chapter 3. 
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(Continued) Table A.1:  Complete list of SEP detected peptides and validation 
methods used to confirm them from chapter 3. 
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Table A.2: Complete list of detected peptides from SEPs identified in chapter 
3 along with other detected peptides that map to the same SEP.  Detected 
peptides listed in red do not meet the scoring criteria to identify a SEP on their own, 
but when matched with a group of other detected peptides occuring from the same 
sORF contribute to the confidence of the SEP identification. 
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(Continued) Table A.2: Complete list of detected peptides from SEPs identified in chapter 3 
along with other detected peptides that map to the same SEP.  Detected peptides listed in 
red do not meet the scoring criteria to identify a SEP on their own, but when matched with a 
group of other detected peptides occuring from the same sORF contribute to the 
confidence of the SEP identification. 
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(Continued) Table A.2: Complete list of detected peptides from SEPs identified in chapter 
3 along with other detected peptides that map to the same SEP.  Detected peptides listed 
in red do not meet the scoring criteria to identify a SEP on their own, but when matched 
with a group of other detected peptides occuring from the same sORF contribute to the 
confidence of the SEP identification. 
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Table A.3:  List of detected peptides from SEPs identified in chapter 3 along with 
start codons, SEP length and Chromosome coordinates.  
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(Continued) Table A.3:  List of detected peptides from SEPs identified in chapter 3 
along with start codons, SEP length and chromosome coordinates.  
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